lansoprazole has been researched along with amoxicillin in 464 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 100 (21.55) | 18.2507 |
2000's | 244 (52.59) | 29.6817 |
2010's | 110 (23.71) | 24.3611 |
2020's | 10 (2.16) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Campillo, NE; Guerra, A; Páez, JA | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Ogura, K; Ota, S; Shimada, T; Terano, A | 1 |
Fujita, N; Hisano, K; Kobayashi, T; Kurokawa, I; Ochiai, T; Sugiyama, T; Yabana, T; Yachi, A | 1 |
Arai, H; Furuta, T; Futami, H; Hanai, H; Kaneko, E | 1 |
Asaka, M; Kagaya, H; Katagiri, M; Katoh, M; Kudoh, M; Takeda, H | 1 |
Itoh, H; Nakata, H; Nishioka, S | 1 |
Harasawa, S; Kobayashi, H; Kurumada, T; Miwa, T; Ohta, U; Shirai, T; Takagi, A | 1 |
Fukuda, Y; Okui, M; Shimoyama, T; Tonokatsu, Y; Yamamoto, I | 1 |
Asagoe, K; Dekigai, H; Kusaka, S; Maeda, S; Matsumoto, M; Mizuno, M; Murakami, M; Saita, H; Seki, M; Takahashi, Y | 1 |
Bigard, MA; Choné, L; Fléjou, JF; Grignon, Y | 1 |
Lamouliatte, H | 1 |
Annibale, B; Biancone, L; Capurso, L; Delle Fave, G; Luzza, F; Marcheggiano, A; Pallone, F; Torsoli, A | 1 |
Arakawa, T; Fukuda, T; Higuchi, K; Kimura, S; Kobayashi, K; Uchida, T | 1 |
Bang, CJ; Berstad, A; Hatlebakk, JG; Hausken, T; Nesje, LB | 1 |
Hentschel, E; Schütze, K | 1 |
Bargiggia, S; Bianchi Porro, G; Colombo, E; Maconi, G; Parente, F | 1 |
Cammarota, G; Fedeli, G; Gasbarrini, G; Montalto, M; Papa, A; Tursi, A | 1 |
Baniukiewicz, A; Bielański, W; Gabryelewicz, A; Hahn, EG; Jedynak, M; Konturek, PC; Konturek, SJ; Kwiecień, N; Sito, E | 1 |
Isoda, K; Itakura, Y; Itoyama, S; Matsumura, O; Mitarai, T; Murakawa, M; Tamura, H; Tokushima, H | 1 |
Asaka, M; Hokari, K; Kagaya, H; Katagiri, M; Kato, M; Koshiyama, T; Kudo, M; Nishikawa, K; Sugiyama, T; Sukegawa, M; Takeda, H | 1 |
Maruyama, M | 1 |
Kawano, S; Murakami, M; Saita, H; Tsuji, S | 1 |
Fukuda, S; Fukuda, Y; Munakata, A; Shimoyama, T; Yoshida, Y | 1 |
Ishino, Y; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Takimoto, T; Taniguchi, Y; Yamamoto, H; Yoshida, Y | 1 |
Fukuda, Y; Shimoyama, T; Tamura, K; Tonokatsu, Y; Tsujiai, T | 1 |
Aller, R; Alvarez Baleriola, I; Bermejo, F; Boixeda, D; Gisbert, JP; Martín de Argila, C | 1 |
Cammarota, G; Cuoco, L; Fedeli, G; Gasbarrini, G; Montalto, M; Papa, A; Tursi, A; Veneto, G | 1 |
Cole, RA; el-Zimaity, HM; Genta, RM; Graham, DY; Malaty, H | 1 |
Arai, H; Baba, S; Furuta, T; Futami, H; Kaneko, E | 1 |
Hirose, H; Isoda, K; Itoyama, S; Matsumura, O; Mitarai, T; Murakawa, M; Sekine, S; Tamura, H; Tokushima, H | 1 |
Amano, K; Goto, A; Kondo, H; Moriwaki, H; Muto, Y; Seko, A; Shimizu, H; Sugie, S; Takagi, S; Yoshimi, N | 1 |
Adachi, H; Ahmed, T; Hori, T; Matsubara, T; Nakahara, A; Sumazaki, R; Takita, H; Yamada, M | 1 |
Daskalopoulous, G; Hazell, SL; Massey, D; Mitchell, HM | 1 |
Akahane, T; Akamatsu, T; Gotoh, A; Katsuyama, T; Kawakami, Y; Kiyosawa, K; Shimizu, T | 1 |
Lambert, JR; Midolo, PD; Turnidge, JD | 1 |
Kimura, M; Seki, H; Urakami, Y | 1 |
Chambers, S; Gould, SR; Lim, AG; Walker, C | 1 |
Flury, R; Fried, M; Kayser, S; Wirth, HP; Zbinden, R | 1 |
Hoffman, JS | 1 |
Hirakawa, T | 1 |
Matsukura, N | 1 |
Ammon, S; Klotz, U; Treiber, G | 1 |
Harris, A | 1 |
Haber, M; Kidd, S; Riff, DS; Rose, P; Siepman, N; Weissfeld, A | 1 |
Arora, A; Graham, D; Haber, M; Harford, W; Lanza, F; Rose, P; Siepman, N; Weissfeld, A | 1 |
Jaup, BK | 1 |
Axon, AT; Chalmers, DM; Dixon, MF; Langworthy, H; Moayyedi, P; Shanahan, K; Tompkins, DS | 1 |
Malfertheiner, P; Mégraud, F | 1 |
Fujiki, K; Horiuchi, T; Ohkusa, T; Shimoi, K; Suzuki, S; Takashimizu, I | 1 |
Akamatsu, T; Gotoh, A; Katsuyama, T; Kawakami, Y | 1 |
Fennerty, MB | 1 |
Bardhan, KD; Cooper, BT; Dixon, MF; Harris, AW; Kerr, GD; Langworthy, H; Levi, S; Misiewicz, JJ; O'Morain, C; Piper, D | 2 |
Boku, N; Ohtsu, T | 1 |
Hibi, T; Ishii, H; Iwai, N; Miyayama, A; Mori, M; Oonuki, M; Suzuki, H; Suzuki, M; Tsunematsu, N | 1 |
Cho, SW; Hahm, KB; Joo, HJ; Kim, JH; Kim, YS; Lee, KJ; Yim, H | 1 |
Collins, BJ; Coombs, GW; Forbes, GM; McCullough, CA; Robins, PD | 1 |
Johnsen, R; Lindsetmo, RO; Revhaug, A | 1 |
Freston, J; Haber, M; Krause, R; Rose, P; Sahba, B; Schwartz, H; Siepman, N; Weissfeld, A | 1 |
Arai, H; Baba, S; Furuta, T; Futami, H; Hanai, H; Kajimura, M; Kaneko, E; Takashima, M | 1 |
Honda, T; Matsumoto, T; Mori, K; Nagatomi, Y; Takaba, M; Tsuneoka, H | 1 |
Barbet, JP; Benhamou, PH; Bergeret, M; Dupont, C; Gendrel, D; Kalach, N; Raymond, J | 1 |
Ikezawa, K; Kashimura, H; Mahmudul, H; Matsuzaki, Y; Mutoh, H; Nakahara, A; Tanaka, N; Yanaka, A | 1 |
Arai, H; Furuta, T; Futami, H; Hanai, H; Kaneko, E; Takashima, M | 1 |
Bierti, L; Bortoli, A; Colombo, E; Fertitta, AM; Lanzi, GL; Minoli, G; Spinzi, GC; Venturelli, R | 1 |
Ahuja, V; Bal, C; Dhar, A; Sharma, MP | 1 |
Benhamou, PH; Bergeret, M; Dupont, C; Gendrel, D; Kalach, N; Raymond, J; Senouci, L | 1 |
Hashimoto, Y | 1 |
Kaitani, K; Kita, T; Murakami, M; Nishio, K; Saita, H; Sou, Y; Takahashi, Y | 1 |
Higashi, Y; Kashima, K; Kodama, T; Sasaki, Y; Sawai, N; Tanahashi, T; Tatsumi, Y; Yamaoka, Y | 1 |
Bazzoli, F; Berretti, D; De Luca, L; Fossi, S; Nicolini, G; Pozzato, P; Ricciardiello, L; Zagari, M | 1 |
Cayla, R; de Mascarel, A; Forestier, S; Joubert-Collin, M; Lamouliatte, H; Mégraud, F; Zerbib, F | 1 |
Asaka, M; Hokari, K; Kagaya, H; Katagiri, M; Kato, M; Kudo, M; Nishikawa, K; Sato, F; Sugiyama, T; Sukegawa, M; Takeda, H | 1 |
Kotze, D; Louw, JA; Marks, IN; Moola, S; Van Rensburg, CJ | 1 |
Howden, CW; Hunt, RH | 1 |
Ariake, K; Fujiki, K; Horiuchi, T; Ishii, K; Kumagai, J; Ohkusa, T; Sakurazawa, T; Shimoi, K; Suzuki, S; Takashimizu, I; Tanizawa, T | 1 |
Asaka, M; Iinuma, K; Kato, S; Ohnuma, K; Ritsuno, H; Sugiyama, T | 1 |
Fujita, T; Kobayasi, I; Mine, T; Suzuki, J | 1 |
Hibi, T; Ishii, H; Kitahora, T; Mori, M; Nagahashi, S; Suzuki, H; Suzuki, M | 1 |
Boixeda, D; Gisbert, JP; Martín de Argila, C | 1 |
Iwasaki, A | 1 |
Harasawa, S; Kouda, K; Kurumada, T; Miwa, T; Shirai, T; Tada, U; Takagi, A; Wada, T; Watanabe, S | 1 |
Kawamura, N; Nakagawa, M; Nakagawa, S; Ooishi, M; Ooizumi, H; Saitou, M; Yoda, Y | 1 |
Miwa, H; Murai, T; Nagahara, A; Ohkura, R; Sato, K; Sato, N; Shimizu, H; Watanabe, S | 1 |
Hassan, M; Ikezawa, K; Kashimura, H; Mutoh, H; Nakahara, A; Sawahata, T; Suzuki, K; Tanaka, N; Watanabe, T | 1 |
Axon, AT; Everett, S; Langworthy, H; Mapstone, NP; Moayyedi, P; Neville, PM; Tompkins, D | 1 |
Gisbert, JP | 1 |
Helbling, A; Pichler, WJ; Schnyder, B | 1 |
Bozzola, L; Di Mario, F; Fortunato, A; Franceschi, M; Leandro, G; Meli, S; Pilotto, A; Rassu, M; Scagnelli, M; Soffiati, G; Valerio, G | 1 |
Della Monica, P; Lombardo, L; Masoero, G; Pera, A | 1 |
Hirai, S; Miwa, H; Murai, T; Nagahara, A; Ohkura, R; Sato, K; Sato, N; Watanabe, S | 1 |
Ducóns, JA; Ferrero, M; Gomollón, F; Guirao, R; Montoro, M; Santolaria, S | 1 |
Fuchs, W; Hörner, M; Schlauch, D; Sellinger, M; Sieg, A | 1 |
Cross, R; Grimley, CE; Illing, RC; Lismore, JR; Loft, DE; Nwokolo, CU; O'sullivan, M; Penny, A; Shebani, M | 1 |
Bravo, LE; Correa, P; DeLany, JP; Mera, R; Realpe, JL | 1 |
Norinder, A; Ohlin, B; Tennvall, GR | 1 |
Cryer, B; Feldman, M; Lee, E; Sammer, D; Spechler, SJ | 1 |
Asaka, M; Ishizuka, J; Kagaya, H; Katagiri, M; Kato, M; Komatsu, Y; Kudo, M; Kudo, T; Nishikawa, K; Sugiyama, T; Sukegawa, M; Takeda, H; Toyota, J | 1 |
Kohigashi, K; Matsukawa, Y; Nakazawa, T; Saita, H; Sekikawa, A; Shio, S; Sou, Y; Takahashi, Y; Yoshinaga, T | 1 |
Fujishiro, M; Gotoda, T; Kondo, H; Oda, I; Ono, H; Saito, D; Yamaguchi, H | 1 |
Hoshiya, S; Ishida, H; Itoh, T; Ninomiya, H; Saito, S; Shingaki, M; Takahashi, S; Tanaka, A; Tokunaga, K; Watanabe, K | 1 |
Carpio, RE; Fock, KM; Ho, J; Hu, FL; Hu, PJ; Huang, NX; Kachintorn, U; Kullavanijaya, P; Lam, SK; Lesmana, L; Li, YY; Manan, C; Perez, JY; Phornphutkul, K; Qian, SC; Wong, BC; Xiao, SD | 1 |
Miwa, H; Murai, T; Nagahara, A; Ogihara, T; Ohkura, R; Ohta, K; Sato, K; Sato, N; Takei, Y; Yamada, T | 1 |
Ducóns, JA; Gomollón, F; Guirao, R; Montoro, M; Santolaria, S; Vera, J | 1 |
Beglinger, C; Drewe, J; Lehmann, FS; Terracciano, L | 1 |
Begum, S; Endo, H; Kawamata, H; Sano, T; Urakami, Y | 1 |
Lin, CH; Peters, J; Rabah, R; Shashidhar, H; Thomas, R; Tolia, V | 1 |
Gonlachanvit, S; Kladchareon, N; Kullavanijaya, P; Mahachai, V | 1 |
Kaushik, SP; Vu, C | 1 |
Ammon, S; Kees, F; Klotz, U; Treiber, G | 1 |
Bhasin, DK; Pathak, CM; Ray, P; Sharma, BC; Singh, K | 1 |
Joubert-Collin, M; Lamouliatte, H; Perie, F | 1 |
Kurosawa, A; Minowa, T; Miwi, H; Murai, T; Nagahara, A; Ohkura, R; Ohtaka, K; Sato, K; Sato, N; Yamada, T | 1 |
Bart, A; Beumer, HJ; Cattoli, G; Klaver, PS; Kuipers, EJ; Kusters, JG; Pot, RG; Robijn, RJ; van der Gaag, I; van Vugt, R; Vandenbroucke-Grauls, CM | 1 |
Andrea Grassi, S; Battaglia, F; Benedetti, E; Bottona, E; Caroli, A; Costan-Biedo, F; Dal Bò, N; De Bastiani, R; Di Mario, F; Germanà, B; Leandro, G; Madia, D; Marcon, V; Marin, R; Monica, F; Olivieri, P; Orzes, N; Pilotto, A; Ronzani, G; Saggioro, A; Tafner, G | 1 |
Howden, CW | 1 |
Huang, AH; Huang, CC; Lin, XZ; Sheu, BS; Wu, JJ; Yang, HB | 1 |
Bock, H; Heep, M; Koop, H; Lehn, N | 1 |
Kawashima, A; Motoo, Y; Ohtsubo, K; Okai, T; Sakai, J; Sawabu, N; Watanabe, H | 1 |
Asaka, M; Hokari, K; Kagaya, H; Kato, M; Komatsu, Y; Mizushima, T; Nishikawa, K; Sugiyama, T; Sukegawa, M; Takeda, H | 1 |
Begum, S; Endo, H; Kawamata, H; Oki, Y; Sano, T; Urakami, Y | 1 |
Akura, Y; Fujiwara, T; Hamazaki, K; Ikeda, Y; Matsumoto, T; Murashima, N; Nishisita, C; Umekawa, Y | 1 |
Aegerter, PH; de Mascarel, A; Lavergne, A; Megraud, F; Molina, T; Palazzo, L; Rambaud, JL; Ruskoné-Fourmestraux, A | 1 |
Asaka, M; Kashiwagi, S; Miyake, K; Nomura, H; Sugiyama, T | 1 |
Asaka, M; Hokari, K; Kagaya, H; Kato, M; Sugiyama, T; Takeda, H | 1 |
Kohgo, Y; Satoh, T; Shibata, N; Tanabe, H; Watari, J; Yokota, K | 1 |
Ohkusa, T; Watanabe, M | 1 |
Harada, H; Kobayashi, S; Miki, H; Ohmori, M; Sotozono, M; Uraoka, T; Yamanoi, Y | 1 |
Arakawa, Y; Ishii, Y; Kato, K; Kawamura, F; Kawamura, Y; Komuro, S; Nagata, T; Nemoto, N; Nishinarita, S; Sugitani, M; Takahashi, Y; Yanai, M | 1 |
Bianchi Porro, G; Imbesi, V; Maconi, G; Parente, F; Russo, A; Vago, L | 1 |
Furuta, T; Hanai, H; Ishizaki, T; Kaneko, E; Ohashi, K; Shirai, N; Sugimura, H; Takashima, M; Xiao, F | 1 |
Alam, E; Mehdi, I; Qureshi, H | 1 |
Endo, H; Higuchi, S; Ohmi, N; Yoshida, H | 2 |
Avidan, B; Bar-Meir, S; Keller, N; Melzer, E | 1 |
Boknik, P; Domschke, W; Fischer, H; Huber, V; Konturek, JW; Luess, H; Neumann, J; Schmitz, W | 1 |
Cathomas, G; Dent, J; Fried, M; Guldenschuh, I; Menne, D; Schwizer, W; Thumshirn, M | 1 |
Hojo, M; Miwa, H; Nagahara, A; Ohkura, R; Sato, K; Sato, N; Yamada, T | 1 |
Kawabe, T; Maeda, S; Ogura, K; Okamoto, M; Omata, M; Shiratori, Y; Yamaji, Y; Yoshida, H | 1 |
Kawamura, K; Kimura, M; Mukai, K; Nakamura, S; Nakamura, T; Sawa, H; Shiku, H; Suzuki, H; Toyoda, H; Yamaguchi, M | 1 |
Adachi, K; Fujishiro, H; Hashimoto, T; Hattori, S; Hirakawa, K; Ishihara, S; Ishimura, N; Kaji, T; Kawamura, A; Kinoshita, Y; Niigaki, M; Sato, H; Watanabe, M | 1 |
Fung, TT; Hui, PK; Lam, KM; Lau, CF; Loo, CK; Tung, SY; Wong, AM | 1 |
Beglinger, C; Burnand, B; Froehlich, F; Gonvers, JJ; Hildebrand, P; Saraga, E; Schneider, C; Vader, JP; Wietlisbach, V | 1 |
Bianchi Porro, G; Cucino, C; Imbesi, V; Maconi, G; Russo, A | 1 |
Burm, M; Faigel, D; Fennerty, MB; Kelly, C; Magaret, N; Peterson, W | 1 |
Aragona, F; Di Vita, G; Leo, P; Montalto, G; Patti, R | 1 |
Hsu, CT; Kuo, CF; Wang, CS; Wang, TH; Yang, JC; Yang, KC | 1 |
Chey, WD; Fendrick, AM | 1 |
Araj, GF; Chahine, C; Chedid, M; Moukhachen, O; Sharara, AI | 1 |
Asaka, M; Hamashima, C; Ikeda, S; Tamamuro, T | 1 |
Asaka, M; Fujioka, T; Fukuda, Y; Kato, M; Kimura, K; Kobayashi, S; Kuwayama, H; Satoh, K; Shimizu, K; Shimoyama, T; Sugiyama, T; Takemoto, T | 2 |
Endo, H; Higuchi, S; Ohmi, N; Ohta, K; Yoshida, H | 1 |
Mai, AL; Mai, KT | 1 |
Ammon, S; Klotz, U; Treiber, G; van Doorn, LJ; Walker, S; Wittig, J | 1 |
Aoyama, N; Okumura, K; Shirasaka, D | 1 |
Bavbek, N; Koçkar, C; Oztürk, M | 1 |
Fujioka, T; Kodama, M; Murakami, K; Nasu, M; Okimoto, T; Sato, R | 1 |
Goto, H; Hino, R; Kikuta, T; Ota, A; Tsuji, H | 1 |
Furukawa, F; Sakurane, M; Shiotani, A | 1 |
Alampi, G; Bazzoli, F; Berretti, D; De Luca, L; Di Pietro, C; Fossi, S; Morelli, P; Nicolini, G; Pozzato, P; Ricciardiello, L; Roda, E; Zagari, RM | 1 |
Chang, CS; Chen, GH; Lai, CH; Poon, SK; Su, J; Wang, WC; Yang, CC | 1 |
Haapiainen, R; Härkönen, M; Kokkola, A; Kosunen, TU; Puolakkainen, P; Rautelin, H; Sipponen, P | 1 |
Barbier, C; Benhamou, PH; Bergeret, M; Dupont, C; Gottrand, F; Husson, MO; Kalach, N; Raymond, J | 1 |
Koyama, H; Nomura, F; Odaka, T; Saisho, H; Yamaguchi, T | 1 |
Andriulli, A; Clemente, R; Festa, V; Merla, A; Perri, F; Quitadamo, M | 1 |
Nakamura, T | 1 |
Asaka, M; Kato, M; Komatsu, Y; Shimizu, Y; Sugiyama, T; Takeda, H | 1 |
Satoh, K | 2 |
Ohkusa, T; Sato, N | 1 |
Miwa, H; Miyazaki, A; Nagahara, A; Sato, N | 1 |
Furuta, T; Shirai, N | 1 |
Mitsuno, Y; Yoshida, H | 1 |
Asaka, M; Kagaya, H; Kato, M | 1 |
Inoue, K; Sugano, K | 1 |
Kurosawa, A; Miwa, H; Sato, N | 1 |
Haruma, K; Kamada, T; Kusunoki, H | 1 |
Sawada, A | 1 |
Chiba, T; Watanabe, T | 1 |
Kawata, H; Satoh, K | 1 |
Azuma, T; Ito, S; Yamazaki, Y | 1 |
Takahashi, S; Tanaka, A | 1 |
Kiriyama, Y; Koizumi, K; Kuwayama, H; Ohara, T; Suga, M; Suzuki, K; Takahashi, M; Takata, H | 1 |
Isomoto, H; Kohno, S | 1 |
Baumann, R; Buri, P; Cunningham, M; Dederding, JP; Gallaz, L; Girard, L; Godin, N; Merki, H; Metry, JM; Sitavanc, R; Wermeille, J; Zelger, G | 1 |
Sugano, K | 1 |
Dhir, V; Laine, L | 1 |
Calvet, X; Gisbert, JP; Vallve, M; Vergara, M | 1 |
Akamatsu, T; Gotoh, A; Ikeno, T; Ishida, K; Kaneko, T; Katsuyama, T; Kawakami, Y; Kiyosawa, K; Ota, H; Shimizu, T; Shimodaira, K; Sugiyama, A | 1 |
Inaba, T; Kawai, K; Miyoshi, M; Mizuno, M; Oguma, K; Okada, H; Take, S; Tsuji, T; Yokota, K | 1 |
Adamek, HE; Riemann, JF; Schilling, D | 1 |
Asaka, M; Shimodan, M; Sugiyama, T; Tsuchida, M; Yokota, K | 1 |
Hirayama, Y; Kanisawa, Y; Kogawa, K; Kohda, K; Koike, K; Kuga, T; Kuroiwa, G; Niitsu, Y; Sato, Y | 1 |
Echizen, H; Nachi, S; Ohnishi, A; Ushiama, H | 1 |
Endo, H; Higuchi, S; Ohmi, N; Ohta, K; Suga, T; Yoshida, H | 1 |
Fujimoto, K; Fujise, T; Ishibashi, S; Iwakiri, R; Kawasaki, S; Kikkawa, A; Oda, K; Ootani, A; Ootani, H; Sakata, H; Shimoda, R; Tadano, J; Tsunada, S; Yoshida, T | 1 |
Boon, YH; Cheng, CS; Chian, LC; Chiu, TC; Kaushik, S; Vu, C | 1 |
Nakamura, T; Terano, A | 1 |
Chen, JH; Lin, MD; Lin, YS; Lo, CY; Sheu, BS; Wu, HW; Wu, JJ | 1 |
Endo, H; Kohno, Y; Suga, T; Yoshida, H | 1 |
Furukawa, K; Hisabe, T; Imamura, K; Kanda, M; Kikuchi, M; Matsui, T; Ohshima, K; Tsuda, S; Yao, T | 1 |
Abe, H; Arita, T; Fujioka, T; Kagawa, J; Kodama, M; Murakami, K; Nasu, M; Okimoto, T; Sato, R; Sato, S | 1 |
Chuang, CH; Huang, AH; Sheu, BS; Wu, JJ; Yang, HB | 1 |
Borner, K; Koeppe, P; Kotwas, J; Lode, H; Mainz, D | 1 |
Kawano, S | 1 |
Chung, IS; Chung, KW; Kim, JI; Kim, JK; Park, SH; Sun, HS | 1 |
Habu, Y; Hayakumo, T; Inokuchi, H; Kawabata, H; Kawai, K; Kimoto, K; Kiyota, K; Kobayashi, M; Kutsumi, H; Mizuno, S; Nakajima, M; Oyasu, K; Tomioka, H | 1 |
Aoyama, N; Kasuga, M; Kita, T; Kuroda, K; Maekawa, S; Miki, I; Okumura, K; Sakaeda, T; Sakai, T; Shirasaka, D; Tamura, T; Wambura, CM | 1 |
Arima, N; Tsudo, M | 1 |
Sano, T; Urakami, Y | 1 |
Furusu, H; Inoue, K; Isomoto, H; Kohno, S; Mizuta, Y; Murase, K; Murata, I; Nishiyama, H; Omagari, K; Shikuwa, S | 1 |
Matsuda, M; Noda, Y; Takemori, Y | 1 |
Asaka, M | 2 |
Hamajima, N; Ikehara, Y; Matsuo, K; Matsuura, A; Nakamura, T; Suzuki, T; Tajima, K; Tominaga, S | 1 |
Chayama, K; Haruma, K; Ito, M; Kamada, T; Masuda, H; Miyamoto, M; Nishisaka, T; Sumioka, M; Tanaka, S; Yoshihara, M | 1 |
Huang, AH; Huang, JJ; Sheu, BS; Wu, JJ; Yang, HB | 1 |
Ford, A; Moayyedi, P | 1 |
Chen, TK; Huang, SH; Lai, YC; Lee, CL; Wang, TH; Wu, CH; Yang, SS | 1 |
Fujita, I; Kato, S; Masuda, G; Matsukura, N; Tajiri, T; Togashi, A; Tokunaga, A; Yamada, N | 1 |
Uthaisaengsook, W | 1 |
Demleitner, K; Fischbach, W; Fuchs, W; Layer, P; Leodolter, A; Malfertheiner, P; MOssner, J; Stolte, M | 1 |
Cohen, L; Fedorak, RN; Lambert, J; Vanjaka, A; Veldhuyzen van Zanten, S | 1 |
Cisneros, G; Gurney, M; Jarjoura, D; Lara, LF; Moauro, B; Polen, A; Rutecki, G; Van Ness, M; Whittier, F | 1 |
Hoshino, Y; Ishii, H; Kurabayashi, K; Masaoka, T; Minegishi, Y; Nomura, S; Suzuki, H; Suzuki, M | 1 |
Chan, CK; Chan, OO; Chu, KM; Hu, HC; Hui, WM; Kwok, KF; Lai, KC; Lam, SK; Wong, BC; Wong, WM | 1 |
Aoyama, N; Fukuda, M; Kachi, M; Kasuga, M; Kuroda, K; Maekawa, S; Miki, I; Shirasaka, D; Tamura, T; Wambura, C; Watanabe, Y | 1 |
Inaba, T; Ishiki, K; Mizuno, M; Nagahara, Y; Oguma, K; Okada, H; Shiratori, Y; Take, S; Yamamoto, K; Yokota, K; Yoshida, T | 1 |
Furuta, T; Ishizaki, T; Ohashi, K; Shirai, N; Sugimoto, M | 1 |
Aiba, M; Hamaguchi, K; Katsube, T; Konno, S; Ogawa, K | 1 |
El-Omar, EM; Furuta, T; Ishizaki, T; Ohashi, K; Rabkin, CS; Shirai, N; Sugimura, H; Xiao, F | 1 |
Asaka, M; Sugiyama, T | 1 |
Ahuja, V; Bal, CS; Chaudhary, A; Das, B; Pandey, RM; Sharma, MP | 1 |
Amarapurkar, A; Amarapurkar, D; Das, HS; Makesar, M | 1 |
Ahuja, V; Bal, C; Bhatia, V; Das, B; Sharma, MP | 1 |
Altintas, E; Aydin, O; Camdeviren, H; Sezgin, O; Ulu, O | 1 |
Fujiyama, Y; Inoue, T; Kakinoki, R; Sakabe, H; Yagi, Y; Yoshikawa, K | 1 |
Asaumi, N; Niiya, K; Niiya, M; Shibakura, M; Tanimoto, M; Yoshida, C | 1 |
Karaoglu, AO; Yasa, MH; Yukselen, V | 1 |
Cucchiara, S; de'Angelis, GL; Ferzetti, A; Franco, MT; Kuvidi, M; Lerro, P; Marinello, D; Oderda, G; Pensabene, L; Romano, C; Strisciuglio, P | 1 |
Ishii, H; Kamiya, AG; Masaoka, T; SuzukiKurabayashi, HK | 1 |
Itoh, K; Itoh, M; Joh, T; Kataoka, H; Kondo, Y; Nomura, T; Ohara, H; Oshima, T; Sasaki, M; Tanida, S | 1 |
Güliter, S; Kandilci, U | 1 |
Bago, J; Bago, P; Belosić Halle, Z; Bevanda, M; Bilić, A; Galović, A | 1 |
Fujioka, T; Kodama, M; Miyajima, H; Murakami, K; Nasu, M; Ogata, M; Ohtsuka, E; Okimoto, T; Saburi, Y; Sato, R; Watanabe, K | 1 |
Cao, X; Kaminishi, M; Kumagai, T; Mizoshita, T; Nozaki, K; Shimizu, N; Tatematsu, M; Tsukamoto, T | 1 |
Fukuda, S; Fukushi, M; Mikami, T; Munakata, A; Shimoyama, T | 1 |
Fujioka, T; Kashimura, K; Kodama, M; Miura, M; Miyajima, H; Murakami, K; Nasu, M; Okimoto, T; Ootsu, S; Sato, R; Watanabe, K | 1 |
Iinuma, K; Kato, S; Konno, M; Maisawa, S; Nakayama, Y; Shimizu, T; Tajiri, H; Toyoda, S; Yoshimura, N | 1 |
Hirashima, N; Ito, K; Kato, A; Kato, H; Kondo, H; Matsunaga, S; Nukaya, H; Sakakibara, K; Sakamoto, T; Tanaka, Y | 1 |
Asaoka, D; Hojo, M; Iijima, K; Kawabe, M; Kurosawa, A; Miwa, H; Miyazaki, A; Nagahara, A; Ohkusa, T; Sato, N; Terai, T | 1 |
Imase, K; Ishida, H; Itoh, T; Kai, A; Sugano, H; Takahashi, S; Tanaka, A; Tokunaga, K; Watanabe, K | 1 |
Iinuma, K; Kato, S; Minoura, T; Ohyauchi, M; Ozawa, K; Sekine, H; Shimosegawa, T | 1 |
Fukuda, Y; Hori, K; Matsumoto, T; Miwa, H; Ohkusa, T; Shintani, S; Tanaka, J; Tomita, T | 1 |
de Mascarel, A; Dubus, P; Lavergne-Slove, A; Megraud, F; Merlio, JP; Ruskone-Fourmestraux, A | 1 |
Chang, CC; Chen, SH; Fang, CL; Hsieh, CR; Lee, YJ; Lien, GS; Lou, HY; Pan, S | 1 |
Feng, LY; Jiang, SL; Yao, XX | 1 |
Färkkilä, MA; Heikkinen, MT; Koivisto, TT; Koskenpato, JP; Rautelin, HI; Voutilainen, ME | 1 |
Caner, B; Gedik, GK; Karaduman, A; Sivri, B | 1 |
Cartell, A; Edelweiss, MI; Francesconi, CF; Mazzoleni, LE; Ott, EA; Prolla, JC; Rivero, LF; Sander, GB; Somm, G; Theil, AL; Uchôa, DM; Wortmann, AC | 1 |
Niv, Y | 2 |
Cao, Q; Si, JM; Wu, JG | 1 |
Egashira, T; Furuta, T; Hishida, A; Ishizaki, T; Kenmotsu, K; Kodaira, M; Nagano, M; Nakamura, A; Ohashi, K; Sagehashi, Y; Shirai, N; Sugimoto, M; Ueda, K; Yoneyama, M | 1 |
Akamatsu, T; Hidaka, E; Matsuzawa, K; Okiyama, Y; Ota, H; Sano, K | 1 |
Furuta, T; Hishida, A; Ishizaki, T; Nakamura, A; Shirai, N; Sugimoto, M | 1 |
Beinborn, M; Ishida, H; Nagamatsu, S; Takahashi, S; Watanabe, K | 1 |
Asaka, M; Ehira, N; Imamura, M; Kanamori, H; Kawamura, T; Masauzi, N; Mori, A; Obara, S; Ogura, N; Tanaka, J; Tsutsumi, Y; Umehara, S; Yamato, H | 1 |
Klotz, U; Schwab, M; Treiber, G | 1 |
Abasiyanik, MF; Huten, O; Salih, BA; Sander, E; Saribasak, H | 1 |
Cho, YS; Kim, SS; Konkin, TA; Meitner, P; Moss, SF; Resnick, MB | 1 |
Carvalhaes, A; Magalhães, AF; Natan-Eisig, J; Paraíso-Ferraz, JG; Trevisan, M; Zaterkaad, S | 1 |
Arai, D; Chen, G; Fukuchi, K; Gomi, K; Kikuchi, R; Takeuchi, Y | 1 |
Baggett, HC; Bruce, MG; Dunaway, E; Gessner, BD; Gold, BD; Muth, PT; Parkinson, AJ | 1 |
Hibi, T; Ishii, H; Masaoka, T; Sakai, G; Suzuki, H | 1 |
Ateş, Y; Bağci, S; Ciğerim, M; Dağalp, K; Kadayifçi, A; Karslioğlu, Y; Savaş, MC; Uygun, A; Yeşilova, Z | 1 |
Cengiz, DU; Güliter, S; Keleş, H; Kolukisa, E; Ozkurt, ZN | 1 |
Aoyagi, K; Maeda, K; Nishiyama, M; Sakisaka, S | 1 |
Kawai, T; Kawakami, K; Moriyasu, F; Takagi, Y | 1 |
Furuta, T; Miura, S; Okudaira, K; Shirai, N; Sugimoto, M | 1 |
Takeda, H | 1 |
Yanaka, A; Zhang, S | 1 |
Nagahara, A; Sato, N | 1 |
Furuta, T; Nakamura, A; Shirai, N; Sugimoto, M | 1 |
Bray, R; Hiratsuka, H; Hiratsuka, T; Kimura, K; Suzuki, T; Tamura, K | 1 |
Fujishiro, M; Kobayashi, K; Oka, M; Omata, M | 1 |
Fujishiro, M; Ichinose, M; Oka, M; Omata, M | 1 |
Konno, M | 1 |
Katoh, H; Kuwano, H; Miyazaki, T; Tsukada, K | 1 |
Bertin, P; Broutet, N; Combe, B; Joubert-Collin, M; Lamouliatte, H; Mégraud, F; Perié, F; Schaeverbeke, T; Zerbib, F | 1 |
Barros, SG; Cartell, A; Edelweiss, MI; Francesconi, CF; Fritscher, LG; Mazzoleni, LE; Ott, EA; Polanczyk, CA; Prolla, JC; Rivero, LF; Sander, GB; Theil, AL; Uchôa, DM; Wortmann, AC | 1 |
Asano, M; Sato, Y; Shimizu, T; Taniwaki, H; Tsuji, D | 1 |
Chan, AO; Chan, CK; Chu, KM; Fung, FM; Gu, Q; Lai, KC; Tong, TS; Wong, BC; Wong, WM; Yee, YK | 1 |
Ariyama, I; Furusyo, N; Hayashi, J; Kochi, S; Kubo, N; Murata, M | 1 |
Asaka, M; Kato, M; Katsuyama, T; Kikuchi, S; Tominaga, S | 1 |
Arakawa, T; Asaka, M; Fujioka, T; Haruma, K; Ishii, H; Kinoshita, Y; Kobayashi, K; Sakaki, N; Sakamoto, C; Shimosegawa, T; Sugiyama, T; Takahashi, S; Terano, A; Yoshikawa, T | 1 |
Hamajima, N; Hirose, K; Ito, H; Matsuo, K; Nakamura, T; Saito, T; Sawaki, A; Suzuki, T; Tajima, K; Wakai, K; Yamao, K | 1 |
Classen, M; Li, J; Lin, SR; Liu, WD; Ma, JL; Pan, KF; Shen, L; Xiao, SD; You, WC; Zhang, L | 1 |
Hayashi, K; Hisanaga, Y; Ichikawa, H; Kawachi, T; Kawase, N; Kiriyama, S; Kumada, T; Kuzuya, T; Nonogaki, K; Shimizu, J; Sone, Y; Tanikawa, M; Toyoda, H; Yamauchi, T | 1 |
Akyol Erikci, A; Ozturk, A; Sayan, O | 1 |
Ang, TL; Chan, YH; Chua, TS; Fock, KM; Ng, TM; Tan, JY; Teo, EK | 1 |
Fujioka, T; Inoue, K; Kodama, M; Miyajima, H; Murakami, K; Okimoto, T; Ono, M; Otsu, S; Sato, R; Watanabe, K | 1 |
Apikoglu-Rabus, S; Besisik, F; Dulger, G; Izzettin, FV; Sancar, M; Tozun, N | 1 |
Ahlroos, T; Korpela, R; Myllyluoma, E; Rautelin, H; Tynkkynen, S; Veijola, L | 1 |
Fukuda, S; Fukushi, M; Munakata, A; Nakasato, F; Shimoyama, T; Tanaka, M | 1 |
Bertoli Neto, JL; Bertoli, CF; Bueno, AG; Lourenço, LG; Sabbi, AR; Ulbrich, FS | 1 |
Arakawa, Y; Hatta, Y; Hayashi, I; Iwamoto, M; Kato, K; Kurihara, R; Kurosaka, H; Matsukawa, Y; Mizuno, S; Sawada, S | 1 |
Hayashida, Y; Itatsu, T; Kubota, M; Miwa, H; Miyazaki, A; Nagahara, A; Sato, N | 1 |
Cindoruk, M; Deger, SM; Kan, E; Karakan, T; Unal, S; Yetkin, I | 1 |
Ishiki, K; Ishioka, H; Mizuno, M; Nagahara, Y; Oguma, K; Okada, H; Take, S; Yokota, K; Yoshida, T | 1 |
Aoki, T; Itoi, T; Kawai, T; Kawakami, K; Matsumoto, Y; Mikinori, K; Moriyasu, F; Noguchi, N; Rimbara, E; Sasatsu, M; Takagi, Y; Takei, K; Watanebe, K | 1 |
Aslan, M; Bagci, S; Erdil, A; Gunhan, O; Ozel, AM; Uygun, A; Yesilova, Z; Yildiz, O | 1 |
Kamiya, S | 1 |
Anbo, T; Asaka, M; Fujinaga, A; Hagiwara, T; Imamura, A; Kato, M; Nakagawa, M; Nakagawa, S; Shimizu, Y; Suga, T; Takeda, H; Uchida, T; Yamamoto, J | 1 |
Cindoruk, M; Dursun, A; Erkan, G; Karakan, T; Unal, S | 1 |
Furuta, T; Hishida, A; Ikuma, M; Ishizaki, T; Kodaira, C; Nishino, M; Shirai, N; Sugimoto, M | 1 |
Chang, WL; Chen, WY; Cheng, HC; Sheu, BS; Wu, JJ; Yang, HB | 1 |
Furuta, T; Hishida, A; Ikuma, M; Ishizaki, T; Kodaira, C; Kumagai, J; Matsushita, F; Nakajima, H; Nishino, M; Senoo, K; Shirai, N; Sugimoto, M; Umemura, K; Watanabe, H; Yamade, M | 1 |
Arakawa, T; Haruma, K; Higuchi, K; Joh, T; Kobayashi, K; Murakami, K; Sugiyama, T; Suzuki, H; Terano, A; Yoshikawa, T | 1 |
Richter, JA; Seabrook, ME; Shmunes, E | 1 |
Bagci, S; Ilgan, S; Kadayifci, A; Safali, M; Uygun, A | 1 |
Chan, YJ; Chang, WH; Chen, CJ; Chen, MJ; Shih, SC; Wang, TE | 1 |
Harris, EJ; Krishna, U; Peek, RM; Perez-Perez, GI; Romero-Gallo, J; Washington, MK | 1 |
Fujioka, T; Kodama, M; Murakami, K; Okimoto, T; Sato, R; Watanabe, K | 2 |
Hirata, Y; Kawabe, T; Maeda, S; Mitsuno, Y; Ogura, K; Ohmae, T; Okamoto, M; Omata, M; Shibata, W; Watabe, H; Yamaji, Y; Yanai, A; Yoshida, H | 1 |
Amenta, PS; Das, KK; Das, KM; Geng, X; Kohgo, Y; Lin, JJ; Tanabe, H; Tanaka, A; Watari, J | 1 |
Aikawa, C; Matsui, H; Murayama, SY; Nakamura, M; Sekiya, Y; Takahashi, S | 1 |
Cole, CR; Frem, JC; Gold, BD; Shehata, BM | 1 |
Asaka, M; Itoh, T; Kato, M; Kubota, K; Nakagawa, M; Ono, S; Ono, Y; Shimizu, Y | 1 |
Ching, SS; Jenkinson, LR; Sabanathan, S | 1 |
Hungin, AP; Jackson, W; Mason, JM; Raghunath, AS | 1 |
Isomoto, H; Ito, M; Kohno, S; Nishiyama, H; Okamoto, K; Shikuwa, S | 1 |
Cho, YK; Choi, WH; Hong, CH; Hong, EJ; Jeon, WK; Kim, BI; Kim, HJ; Oh, SJ; Park, DI; Park, JH; Shon, CI; Song, MJ | 1 |
Arakawa, T; Fujiwara, Y; Higuchi, K; Hino, M; Koh, K; Nakao, T; Okazaki, H; Oshitani, N; Tanigawa, T; Tominaga, K; Tsumoto, C; Watanabe, K; Watanabe, T; Yamagami, H; Yamane, T | 1 |
Chae, HS; Chang, YW; Cho, CM; Chun, HJ; Chung, IS; Hong, SJ; Jeon, WJ; Jung, HC; Kim, HU; Kim, JG; Kim, JW; Kim, N; Kim, SW; Kim, TN; Lee, GH; Lee, KJ; Lee, OJ; Lee, SW; Park, CG; Park, CH; Park, JJ; Park, JY; Park, KS; Park, MI; Park, SH; Seo, GS; Seol, S; Shim, KN; Shin, JE; Shin, WC; Shin, YW; Song, GA; Won, SY; Yoon, BC | 1 |
Bengtsson, C; Granström, M; Hoang, TT; Nguyen, GK; Nguyen, TV; Phung, DC; Sörberg, M | 1 |
Cheon, JH; Kim, JH; Kim, TI; Kim, WH; Lee, SK; Lee, YC | 1 |
Abdullahi, M; Annibale, B; Capoccia, D; Leonetti, F; Marcheggiano, A; Osborn, J; Severi, C; Tari, R; Vannella, L | 1 |
Balkarli, A; Baştürk, A; Cerçi, S; Senol, A; Songür, Y | 1 |
Fukase, K; Kawata, S; Mabe, K; Matsuda, T; Oizumi, H; Shibata, A; Takahashi, M; Takeda, H; Tsukuma, H | 1 |
ASAKA, M; HASHINO, S; IMAMURA, M; KAHATA, K; KONDO, T; MORITA, R; OKADA, K; ONOZAWA, M; TAKAHATA, M | 1 |
Mahachai, V; Sirimontaporn, N; Thong-Ngam, D; Tumwasorn, S | 1 |
Angelini, R; Pontone, P; Pontone, S; Standoli, M | 1 |
Hori, S; Inoue, M; Kawahara, Y; Kawano, S; Okada, H; Onishi, Y; Shiratori, Y; Takenaka, R; Toyokawa, T; Yamamoto, K | 1 |
Cristofari, F; De Francesco, V; Hassan, C; Iegri, C; Zullo, A | 1 |
Dutta, U; Kochhar, R; Noor, MT; Sidhu, GS; Singh, K; Udawat, H; Vaiphei, K | 1 |
Hirata, Y; Joh, T; Kamiya, T; Kasugai, K; Kataoka, H; Mizoshita, T; Ogasawara, N; Sasaki, M; Shimura, T; Tanida, S; Utsumi, K | 1 |
Bağci, S; Erçin, CN; Kantarcioğlu, M; Kilciler, G; Polat, Z; Toros, AB; Uygun, A | 1 |
Akgöllü, E; Akkiz, H; Bayram, S; Bekar, A; Ozdil, B; Sandikçi, M | 1 |
Ashida, C; Higashida, A; Kawara, F; Mamori, S; Ohnishi, K; Senda, E; Takeda, A; Yamada, H | 1 |
Abue, M; Kon, H; Noguchi, T; Nomura, E; Onodera, H; Ota, Y; Suzuki, M; Suzuki, S; Tateno, H; Uchimi, K | 1 |
Gon, Y; Hemmi, A; Iwamoto, M; Kato, K; Matsukawa, Y; Mizuno, S; Sawada, S; Shirinskaya, N; Takeuchi, J | 1 |
Arisawa, T; Hirata, I; Ishizuka, T; Maeda, Y; Nakamura, M; Okubo, M; Shibata, T; Tahara, T; Yonemura, J; Yoshioka, D | 1 |
Hibi, T; Hosoe, N; Ikeda, Y; Imaeda, H; Iwao, Y; Kameyama, K; Kizaki, M; Ogata, H; Suzuki, H; Yaguchi, T | 1 |
Bekar, O; Gulten, M; Yilmaz, Y | 1 |
Aydemir, S; Cabuk, M; Demircan, N; Eren, H; Harmandar, FA; Tekin, IO | 1 |
Kilic, ZM; Nadir, I; Ozin, Y; Sezgin, O; Yonem, O | 1 |
Mahachai, V; Sirimontaporn, N; Thong-Ngam, D; Tumwasorn, S; Vilaichone, RK | 1 |
Asaka, M; Furukawa, K; Furuta, T; Inaba, T; Ishii, N; Kamoshida, T; Kato, M; Konda, Y; Nomura, H; Sasaki, M; Shirai, T; Sugimoto, M; Tomita, T | 1 |
Ince, AT; Kesici, B; Polat, Z; Saglam, M; Toros, AB; Uygun, A | 1 |
Akkan Çetinkaya, Z; Düzgün, S; Erhan Altunöz, M; Günes, P; Güzelbulut, F; Ovünç Kurdas, O; Sezikli, M | 1 |
Goto, Y; Hamajima, N; Inoue, S; Kamiya, Y; Kawai, S; Kondo, T; Kurata, M; Tamura, T | 1 |
Demir, M; Erbayrak, M; Gokturk, HS; Sakalli, M; Unler, GK; Yilmaz, U | 1 |
Choi, JH; Chun, HJ; Jung, SW; Kim, JH; Kim, SY; Koo, JS; Lee, SW; Park, JJ; Yim, HJ | 1 |
Bay, A; Coskun, E; Leblebisatan, G; Yalcin, AS | 1 |
Çetinkaya, ZA; Coşgun, S; Güzelbulut, F; Kurdaş, OÖ; Sezikli, M; Yeşil, A | 1 |
Anderson, GL; Baker, LH; Bravo, LE; Chey, WD; Correa, P; Crowley, JJ; Dominguez, RL; Ferreccio, C; Goodman, GE; Greenberg, ER; Herrero, R; Lazcano-Ponce, EC; Martínez, ME; Meza-Montenegro, MM; Morgan, DR; Peña, EM; Peña, R; Salazar-Martínez, E; Torres, J; Valdivieso, M | 1 |
Francesconi, CF; Mazzoleni, LE; Sander, GB | 1 |
Basu, PP; Flynn, M; Krishnaswamy, N; Pacana, T; Rayapudi, K; Shah, NJ | 1 |
Annibale, B; Hassan, C; Sbrozzi-Vanni, A; Severi, C; Vannella, L; Zullo, A | 1 |
Chang, LL; Chen, YH; Huang, YK; Kuo, CH; Kuo, FC; Lee, YC; Wang, SS; Wang, TH; Wang, WM; Wu, DC; Wu, MC | 1 |
Erdur, B; Gurbuz, ED; Ozturk, Y; Yilmaz, O | 1 |
Inoue, H; Inoue, T; Maruoka, Y; Nakajima, S | 1 |
Choi, JH; Chun, HJ; Hyun, JJ; Jung, SW; Kim, SY; Koo, JS; Lee, SW; Park, JJ; Yim, HJ | 1 |
Funakoshi, R; Kawai, N; Kobayashi, K; Ueno, F; Yamada, Y; Yokoyama, H | 1 |
Bengtsson, C; Granström, M; Hoang, TT; Nguyen, GK; Nguyen, TV; Phung, DC; Sörberg, M; Yin, L | 1 |
Chung, JW; Hahm, KB; Jeong, JY; Jung, YK; Kim, JH; Kim, YJ; Kwon, KA; Lee, JJ; Lee, SM; Yun, SC | 1 |
Chang, CY; Chang, WH; Chen, CC; Chen, MJ; Fang, YJ; Hsu, SJ; Hsu, YC; Lee, JY; Lee, YC; Lin, JT; Liou, JM; Luo, JC; Shun, CT; Tseng, CH; Tseng, PH; Wang, HP; Wu, MS; Yang, UC | 1 |
Amagai, K; Ando, T; Asaka, M; Furuta, T; Hori, S; Inaba, T; Inoue, S; Inui, Y; Iwamoto, J; Kamoshida, T; Kato, M; Kodama, M; Kudo, M; Mabe, K; Miwa, J; Mizuno, S; Murakami, K; Nakajima, T; Nomura, H; Ohkusa, T; Okimoto, T; Oshima, T; Sasaki, M; Satoh, K; Suganuma, T; Take, S; Tomita, T; Tomokane, T; Yamamoto, S | 1 |
Cho, WY; Choi, IJ; Jung, HC; Keum, B; Kim, JG; Kim, SG; Lee, JH; Lee, YC; Park, BJ; Park, SK; Song, HJ | 1 |
Anderson, GL; Baker, LH; Bravo, LE; Chey, WD; Correa, P; Crowley, JJ; Dominguez, RL; Ferreccio, C; Goodman, GE; Greenberg, ER; Herrero, R; Lazcano-Ponce, EC; Martínez, ME; Meza-Montenegro, MM; Morgan, DR; Peña, EM; Peña, R; Salazar-Martínez, E; Sexton, R; Torres, J; Valdivieso, M | 1 |
Malfertheiner, P | 1 |
Imai, Y; Inokuma, T; Matsumoto, T | 1 |
Botero, ML; Cárdenas, A; Forero, JD; Rey, M; Sierra, F | 1 |
Dubois, A; Francis, J; Jia, Y; Liu, H; McAvoy, TJ; Merrell, DS; Nieroda, C; Sardi, A; Semino-Mora, C; Studeman, K; Testerman, TL; Whitmire, JM | 1 |
Chen, A; Chen, JJ; Hsu, PI; Hsu, WH; Kuo, CH; Kuo, FC; Liu, CJ; Liu, MK; Lu, CY; Su, YC; Wu, DC; Wu, IC; Yu, FJ | 1 |
Asaoka, D; Ito, M; Kawai, T; Kawakami, K; Kurihara, N; Matsuhisa, T; Mine, T; Mizuno, S; Nagahara, A; Nishizawa, T; Ohkusa, T; Omata, F; Sakaki, N; Sasaki, H; Suzuki, H; Suzuki, M; Takahashi, S; Tokunaga, K; Torii, A | 1 |
Benzer, E; Bilir, G; Gokcan, H; Onal, IK; Oztas, E | 1 |
Doğan, Z; Ergül, B; Filik, L; Sarikaya, M | 2 |
Ateş, Y; Avşar, E; Aytuğ, N; Bektaş, A; Bölükbaş, C; Dinçer, D; Ellidokuz, E; Erzin, Y; Güliter, S; Kaymakoğlu, S; Kocakaya, O; Onuk, MD; Poturoğlu, S; Taşan, G; Tiftikçi, A; Türkay, C; Yıldırım, B; Yılmaz, U | 1 |
Adachi, E; Fujii, T; Iwamoto, A; Kikuchi, T; Koga, M; Koibuchi, T; Ohno, N; Okame, M; Ota, Y; Oyaizu, N; Sato, H; Takaya, S | 1 |
Barbaro, F; Cammarota, G; Campanale, M; Cesario, V; D'Angelo, G; De Pasquale, T; Di Rienzo, TA; Franceschi, F; Gasbarrini, A; Gigante, G; Nucera, E; Ojetti, V; Pecere, S; Rizzi, A; Schiavino, D | 1 |
Abdalla, AF; Al-Hussaini, AS; El-Baz, R; Galal, A; Settin, A | 1 |
Kato, M | 1 |
Akdoğan, RA; Bedir, R; Copur, A; Rakici, H; Yilmaz, A | 1 |
Cho, KB; Ha, CY; Heo, J; Jang, BI; Jeon, SW; Jung, JT; Kim, ES; Kim, EY; Kim, HJ; Kwon, JG; Lee, DW; Lee, SH; Park, KS; Seo, HE | 1 |
Akyon, Y; Bayrak, A; Celikel, C; Ertem, D; Kutluk, G; Tutar, E; Volkan, B | 1 |
Chung, JW; Kim, KO; Kim, SY; Kim, YJ; Kwon, KA; Park, DK | 1 |
Bae, SH; Hyun, MS; Jo, JC; Joo, YD; Kim, DY; Kim, H; Kim, HJ; Kim, MK; Lee, JH; Lee, KH; Lee, SM; Lee, WS; Ryoo, HM; Zang, DY | 1 |
Mahachai, V; Siramolpiwat, S; Srinarong, C; Vilaichone, RK; Wongcha-um, A | 1 |
Asaoka, D; Ito, M; Kawai, T; Kawakami, K; Kurihara, N; Masaoaka, T; Matsuhisa, T; Mine, T; Mizuno, S; Nagahara, A; Nishizawa, T; Ohkusa, T; Omata, F; Sakaki, N; Sasaki, H; Suzuki, H; Suzuki, M; Takahashi, S; Tokunaga, K; Torii, A | 1 |
Akdogan, RA; Ayaz, T; Bedir, R; Rakici, H | 1 |
Chen, YH; Hsu, WH; Huang, CY; Huang, YL; Kuo, FC; Liu, CJ; Lu, CY; Shih, HY; Wang, SS; Wu, DC; Wu, MC | 1 |
Long, C; Zhang, S | 1 |
Cao, Z; Chen, Q; Liang, X; Liao, J; Liu, W; Lu, H; Xiao, S; Zhang, W | 1 |
Aydoğdu, S; Baran, M; Çakır, M; Tümgör, G; Yüksekkaya, HA | 1 |
Hauser, G; JajacKnez, A; Salkic, N; Stimac, D; Vukelic, K | 1 |
Barbuti, RC; Eisig, JN; Iriya, K; Lee, JH; Mattar, R; Navarro-Rodriguez, T; Queiroz, EC; Silva, FM | 1 |
Hashimoto, Y; Hiki, N; Honda, M; Kamiya, S; Kumagai, K; Mine, S; Nunobe, S; Ohashi, M; Sano, T; Yamaguchi, T | 1 |
Chen, Q; Graham, DY; Liang, X; Liu, W; Lu, H; Xiao, S; Zhang, W | 1 |
Bair, MJ; Chang, CC; Chang, CY; Chang, WH; Chen, CC; Chen, MJ; Fang, YJ; Hsieh, CF; Hsu, YC; Lee, JY; Lee, YC; Lin, JT; Liou, JM; Liou, TC; Liu, TY; Luo, JC; Shun, CT; Tsao, FY; Tseng, CH; Wu, JY; Wu, MS; Yang, TH | 1 |
Chun, J; Kim, BG; Kim, BS; Kim, JS; Kim, JW; Koh, SJ; Lee, KL; Oh, B | 1 |
Bilici, M; Demirci, H; Köktürk, F; Kurt, Ö; Öztürk, K; Üstündağ, Y; Uygun İlikhan, S; Uygun, A | 1 |
Ahmed, MR; Mel-Hennawi, D | 1 |
Bair, MJ; Chang, CC; Chang, CY; Chang, WH; Chen, CC; Chen, CY; Chen, MJ; Chen, PY; Fang, YJ; Hsu, WF; Hung, HW; Lee, JY; Lee, YC; Lin, JT; Liou, JM; Luo, JC; Shun, CT; Tseng, CH; Wu, JY; Wu, MS; Yang, TH | 1 |
Durukan, E; Erhamamci, S; Gokturk, HS; Ozgur, GT; Unler, GK | 1 |
Franceschi, F; Gabrielli, M; Gasbarrini, A; Gasbarrini, G; Lopetuso, LR; Ojetti, V; Petruzziello, C; Scaldaferri, F; Tortora, A | 1 |
Asaka, M; Funao, N; Murakami, K; Nishimura, A; Sakurai, Y; Shiino, M | 1 |
Imamura, T; Imashuku, S; Ohmae, T; Osamura, T; Todo, K | 1 |
Fukayama, M; Hayakawa, Y; Hirata, Y; Koike, K; Niikura, R; Shichijo, S; Ushiku, T; Yamada, A | 1 |
Gotoda, T; Iwatsuka, K; Kusano, C; Moriyama, M; Suzuki, S | 1 |
Ida, A; Miyaki, A; Miyauchi, T; Yamaguchi, K | 1 |
Chen, Q; Fu, Q; Liang, X; Liu, W; Lu, H; Xiao, S; Zhang, W | 1 |
Inoue, H; Ito, M; Kasai, C; Moritani, I; Oya, Y; Shiraki, K; Sugimoto, K; Takase, K; Takei, Y; Tameda, M; Tanaka, J | 1 |
Bair, MJ; Chang, CC; Chang, CY; Chen, CC; Chen, CY; Chen, MJ; Chen, PY; Chen, YN; El-Omar, EM; Fang, YJ; Hsu, WF; Hsu, YC; Hu, WH; Lee, JY; Lee, YC; Lin, JT; Liou, JM; Luo, JC; Sheu, BS; Shun, CT; Tseng, CH; Wu, JY; Wu, MS; Yang, TH | 1 |
Fujisawa, T; Horiuchi, A; Imai, R; Kimura, T; Kiyosawa, K; Kubota, D; Maruyama, M; Matsuda, Y; Miyajima, M; Mori, H; Tanaka, N; Tokutake, K; Wada, S | 1 |
Aktas, AH; Saridag, AM | 1 |
Akay, S; Akpinar, Z; Unsal, B | 1 |
Choi, IJ; Kim, BJ; Kim, JG; Kim, JI; Kim, JJ; Kim, SG; Lee, H; Lee, YC | 1 |
Benedeto-Stojanov, D; Grgov, S; Radovanović-Dinić, B; Tasić, T | 1 |
Coşkun, DÖ; Deniz, K; Gürsoy, Ş; Özbakir, Ö; Yagbasan, A; Yücesoy, M | 1 |
Auesomwang, C; Chey, WD; Kiratisin, P; Leelakusolwong, S; Maneerattanaporn, M; Tanwandee, T | 1 |
Robotis, J; Rokkas, T; Tsiodras, S | 1 |
Irie, K; Kaneko, H; Kondo, M; Maeda, S; Sasaki, T; Shibata, W; Sue, S | 1 |
Shahbazi, S; Vahdat Shariatpanahi, Z | 1 |
Chu, CH; Liao, PH; Lin, YC; Liou, TC; Shih, SC | 1 |
Ji, C; Li, L; Li, Y; Liu, J; Sun, Y; Wang, T; Yang, X; Zuo, X | 1 |
Abagyan, R; Dai, W; Dong, M; Shi, D; Zhang, Y | 1 |
Chayama, K; Kitadai, Y; Masaki, S; Matsuo, K; Matsuo, T; Naito, T; Sentani, K; Takigawa, H; Tanaka, S; Urabe, Y; Yuge, R | 1 |
Baik, GH; Choi, IJ; Jeon, SW; Kim, BJ; Kim, GH; Kim, HS; Kim, HU; Kim, J; Kim, JG; Kim, JI; Kim, JJ; Kim, SG; Kim, SW; Lee, DH; Lee, H; Lee, J; Lee, JY; Lee, YC; Park, MI; Sung, JK; Yoon, SM | 1 |
Bair, MJ; Chang, CM; Chang, CY; Chen, CC; Chen, CY; Chen, MJ; Chen, PY; Chen, YN; Chuang, EY; El-Omar, EM; Fang, YJ; Hsu, WF; Hsu, YC; Lee, JY; Lin, JT; Liou, JM; Lu, TP; Luo, JC; Wu, JY; Wu, MS; Yang, TH | 1 |
Asahina, A; Kikuchi, S; Nobeyama, Y; Saeki, H | 1 |
Jeon, SW; Kwon, YH; Lee, HS; Lee, SW; Nam, SY | 1 |
Choi, IJ; Joo, J; Kim, CG; Kim, YI; Kook, MC; Lee, JY; Park, B | 1 |
Mukhopadhyay, AK; Nandi, SP; Saxena, A | 1 |
Fukuda, K; Fukuda, M; Hirashita, Y; Kawahara, Y; Kodama, M; Kudo, Y; Matsunari, O; Mizukami, K; Murakami, K; Ogawa, R; Okamoto, K; Okimoto, T; Wada, Y | 1 |
Bhatia, S; Chung, H; Huh, KY; Kim, YK; Lee, S; Nakaya, R; Takanami, Y; Yu, KS | 1 |
Hassib, ST; Mostafa, EA; Sharf, MG; Taha, EA | 1 |
Chiu, CT; Chong, CF; Chung, WC; Gu, L; Hou, X; Kudou, K; Meng, F; Sha, W; Wang, J; Zhang, S | 1 |
Chey, WD; Howden, CW; Hunt, BJ; Laine, L; López, LJ; Mégraud, F | 1 |
Ding, YM; Han, ZX; Ji, R; Li, YY; Lin, BS; Zhang, WL | 1 |
55 review(s) available for lansoprazole and amoxicillin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Effect of lansoprazole on Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Microbial Sensitivity Tests; Omeprazole; Tinidazole | 1993 |
[Diagnosis and treatment of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Bacteriological Techniques; Clarithromycin; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Polymerase Chain Reaction; Ranitidine | 1997 |
Efficacy of lansoprazole in eradicating Helicobacter pylori: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Patient Selection; Penicillins; Peptic Ulcer; Randomized Controlled Trials as Topic | 1998 |
[Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Penicillins; Peptic Ulcer; Proton Pump Inhibitors | 1999 |
[Lansoprazole: a review of its role in Helicobacter pylori eradication therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Nitroimidazoles; Omeprazole; Penicillins | 1999 |
[Recent guidelines for the management of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Practice Guidelines as Topic; Proton Pump Inhibitors | 2001 |
[A strategy for second-line anti-Helicobacter pylori therapy in patients with previously failed treatment].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Mixed Function Oxygenases; Omeprazole; Patient Compliance; Polymorphism, Genetic; Proton Pump Inhibitors; Treatment Failure | 2001 |
[Progress of tailor-made treatment of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Asian People; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors | 2002 |
[The outline of medical treatment of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Clarithromycin; Drug Therapy, Combination; Evidence-Based Medicine; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Misoprostol; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors | 2002 |
[Guidelines for the management of Helicobacter pylori infection in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Omeprazole; Practice Guidelines as Topic | 2002 |
[New triple therapy for Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors | 2002 |
[Proton pump inhibitor-based quadruple therapy regimen for Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Bismuth; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Tetracycline | 2002 |
[Effect of PPI/AM re-treatment regimen for the patients with Helicobacter pylori infection after failure of first line eradication therapy by PPI/AC regimens].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Treatment Failure; Treatment Outcome | 2002 |
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Pharmacogenetics; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Treatment Failure | 2002 |
[Ecabet sodium (ECA) + PPI + AMPC therapy for clarithromycin-resistant Helicobacter pylori infections].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Clinical Trials as Topic; Diterpenes; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 2002 |
[Eradication therapy for clarithromycin-resistant and metronidazole-resistant Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Treatment Failure | 2002 |
[Adverse effects of H. pylori eradication therapy and its measure].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Clarithromycin; Diarrhea; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lactobacillus acidophilus; Lansoprazole; Mouth Diseases; Omeprazole; Skin Diseases | 2002 |
[H. pylori eradication therapy and natural history of peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Secondary Prevention | 2002 |
[Peptic ulcer in the elderly].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors | 2002 |
[Proton pump inhibitors: Efficacy of lansoprazole in eradicating Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Depression, Chemical; Drug Therapy, Combination; Enzyme Inhibitors; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 2002 |
[Plaunotol].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug Resistance, Bacterial; Drug Therapy, Combination; Fatty Alcohols; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Neutrophil Activation; Omeprazole; Peptic Ulcer; Prognosis | 2002 |
[Ecabet sodium].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Amoxicillin; Animals; Anti-Ulcer Agents; Diterpenes; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Randomized Controlled Trials as Topic; Secondary Prevention; Urease | 2002 |
[Polaprezinc].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Ulcer Agents; Carnosine; Clarithromycin; Clinical Trials as Topic; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Organometallic Compounds; Peptic Ulcer; Urease; Zinc Compounds | 2002 |
[Helicobacter heilmannii-associated gastritis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Clarithromycin; Drug Therapy, Combination; Gastritis; Helicobacter heilmannii; Helicobacter Infections; Humans; Lansoprazole; Metronidazole; Omeprazole; Organometallic Compounds; Tetracycline | 2002 |
[Practice guidelines for diagnosis and treatment of Helicobacter pylori infections and their application in clinical practice].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Practice Guidelines as Topic; Proton Pump Inhibitors | 2002 |
Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Pantoprazole; Penicillins; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Treatment Outcome | 2002 |
[Eradication therapy of Helicobacter pylori for elderly patients in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Clarithromycin; Drug Interactions; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Omeprazole; Practice Guidelines as Topic | 2002 |
[Helicobacter pylori induced gastritis: recent topics on eradication therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Omeprazole; Penicillins; Proton Pump Inhibitors; Tetracyclines | 2002 |
[New triple therapy for Helicobacter pylori infection in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole | 2003 |
Extragastric mucosa-associated lymphoid tissue lymphoma showing the regression by Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Gastrectomy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Male; Omeprazole; Stomach Neoplasms; Thyroid Neoplasms; Thyroiditis, Autoimmune | 2003 |
[Guidelines in the management of Helicobacter pylori infection in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Microbiology; Omeprazole; Peptic Ulcer; Polyps; Practice Guidelines as Topic; Proton Pump Inhibitors; Societies, Medical; Stomach Neoplasms | 2003 |
How can the current strategies for Helicobacter pylori eradication therapy be improved?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Time Factors | 2003 |
Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Apoptosis; Chemistry, Clinical; Clarithromycin; Drug Therapy, Combination; Gastric Mucosa; Gastrointestinal Diseases; Gerbillinae; Helicobacter Infections; Helicobacter pylori; Japan; Lansoprazole; Omeprazole; Peptic Ulcer; Urease | 2003 |
[Eradication effect of lansoprazole-based triple therapy against H. pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Neoplasms; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Stomach Ulcer | 2004 |
[Evaluation of the efficacy of an Helicobacter pylori eradication treatment for idiopathic thrombocytopenic purpura patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Infective Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Purpura, Thrombocytopenic, Idiopathic | 2004 |
Helicobacter heilmannii infection in a child after successful eradication of Helicobacter pylori: case report and review of literature.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter heilmannii; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Esomeprazole; Gastroesophageal Reflux; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole | 2005 |
[Guidelines in the management of H. pylori infection in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Metronidazole; Omeprazole; Practice Guidelines as Topic; Proton Pump Inhibitors | 2005 |
[Cap polyposis and Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Intestinal Polyposis; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 2005 |
[Concomitant dosing of a H2 receptor antagonist (H2RA) with a triple therapy increases the cure rate of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Enzyme Inhibitors; Famotidine; Gastric Acidity Determination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic | 2005 |
[Triple therapy for eradication of Helicobacter pylori in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Humans; Insurance, Health; Japan; Lansoprazole; Omeprazole; Patient Compliance; Practice Guidelines as Topic; Proton Pump Inhibitors | 2005 |
[Adverse effects of Helicobacter pylori eradication and its prevention].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors | 2005 |
[Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Patient Compliance; Proton Pump Inhibitors; Treatment Outcome | 2005 |
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Treatment Failure | 2005 |
[Comparison between one-week and two-week regimens of new triple therapy in H. pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Time Factors; Treatment Outcome | 2005 |
[Helicobacter pylori eradication therapy for children].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Child; Clarithromycin; Drug Resistance; Drug Therapy, Combination; Enzyme Inhibitors; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Patient Compliance; Proton Pump Inhibitors; Purpura, Thrombocytopenic, Idiopathic; Treatment Outcome | 2005 |
[Eradication of Helicobacter pylori in patients with end-stage renal disease undergoing dialysis treatment].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Dialysis; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Kidney Failure, Chronic; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors | 2005 |
[Cytochrome P450 2C19 genotype -based second line therapy with amoxicillin and lansoprazole after failure of initial helicobacter pylori eradication therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Enzyme Inhibitors; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Pharmacogenetics; Polymorphism, Genetic; Proton Pump Inhibitors; Treatment Failure | 2005 |
[Helicobacter pylori infection and probiotics].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Bifidobacterium; Clarithromycin; Clostridium butyricum; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lactobacillus; Lansoprazole; Probiotics; Saccharomyces | 2007 |
[Regression of MALT lymphoma of the rectum after Helicobacter pylori eradication therapy in a patient negative for Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Rectal Neoplasms | 2010 |
[Expanded indication of National Health Insurance for H. pylori associated gastritis].
Topics: Amoxicillin; Anti-Bacterial Agents; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Metronidazole; National Health Programs; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2014 |
Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Clarithromycin; Doxycycline; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Metronidazole; Proton Pump Inhibitors; Ranitidine; Tetracycline | 2016 |
Topics: Amoxicillin; Anti-Bacterial Agents; Biological Products; Bismuth; Clarithromycin; Drug Therapy, Combination; Dysbiosis; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Phytochemicals; Plant Extracts; Plants, Medicinal; Probiotics | 2020 |
Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Pyrroles; Treatment Outcome | 2023 |
232 trial(s) available for lansoprazole and amoxicillin
Article | Year |
---|---|
Clinical efficacy of lansoprazole-amoxicillin treatment in eradicating Helicobacter pylori: evaluation by the polymerase chain reaction method.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Base Sequence; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Molecular Sequence Data; Omeprazole; Penicillins; Peptic Ulcer; Polymerase Chain Reaction; Proton Pump Inhibitors | 1995 |
Lansoprazole versus lansoprazole plus amoxicillin treatment for eradication of Helicobacter pylori in patients with gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Penicillins; Proton Pump Inhibitors; Stomach Ulcer | 1995 |
Effects of lansoprazole with or without amoxicillin on ulcer healing: relation to eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Duodenal Ulcer; Gastric Juice; Gastric Mucosa; Gastrins; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Penicillins; Pepsinogens; Peptic Ulcer; Proton Pump Inhibitors; Stomach Ulcer | 1995 |
Clinical efficacy of lansoprazole in eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Proton Pump Inhibitors; Stomach Ulcer | 1995 |
Efficacy of lansoprazole and amoxicillin in eradicating Helicobacter pylori: evaluation using 13C-UBT and Monoclonal H. pylori antibody testing.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Antibodies, Bacterial; Antibodies, Monoclonal; Breath Tests; Drug Therapy, Combination; Duodenal Ulcer; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Monitoring, Physiologic; Omeprazole; Penicillins; Pepsinogens; Stomach Ulcer; Urea | 1995 |
Eradication of Helicobacter pylori with lansoprazole, amoxicillin, and plaunotol in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Diterpenes; Drug Therapy, Combination; Duodenal Ulcer; Fatty Alcohols; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors | 1995 |
Combination therapies with a proton pump inhibitor for Helicobacter pylori-infected gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Fatty Alcohols; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors; Recurrence; Stomach Ulcer | 1995 |
Therapeutic effects of lansoprazole on peptic ulcers in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Ampicillin; Anti-Ulcer Agents; Famotidine; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Proton Pump Inhibitors | 1995 |
Lansoprazole and Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulins; Lansoprazole; Middle Aged; Omeprazole | 1993 |
Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Amoxicillin; Anti-Ulcer Agents; Capsules; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Pharyngitis; Stomatitis; Suspensions | 1995 |
Comparison of two lansoprazole-antibiotic combinations (amoxycillin or classical triple therapy) for treatment of H. pylori infection in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Antitrichomonal Agents; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Penicillins; Tinidazole | 1996 |
One week treatment with omeprazole, clarithromycin and tinidazole or lansoprazole, amoxicillin and metronidazole for cure of Helicobacter pylori infection in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Acidity Determination; Gastric Mucosa; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Tinidazole | 1996 |
[Eradication of Helicobacter pylori in patients with end-stage renal disease undergoing dialysis treatment].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ammonia; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Diterpenes; Drug Therapy, Combination; Fatty Alcohols; Female; Gastric Juice; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Peritoneal Dialysis, Continuous Ambulatory; Renal Dialysis | 1996 |
Effects of lansoprazole plus amoxycillin on the cure of Helicobacter pylori infection in Japanese peptic ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Synergism; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Recurrence; Stomach Ulcer | 1996 |
[Effect of treatment with lansoprazole and amoxicillin in combination on healing process of duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Drug Therapy, Combination; Duodenal Ulcer; Duodenoscopy; Female; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors | 1996 |
Ecabet sodium eradicates Helicobacter pylori infection in gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Pepsin A; Protease Inhibitors; Stomach Ulcer | 1996 |
Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Proton Pump Inhibitors | 1996 |
High-dose proton pump inhibitor plus amoxycillin for the treatment or retreatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors | 1996 |
Lansoprazole and amoxycillin: observations on the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Recurrence; Treatment Outcome | 1997 |
[Comparative effect of lansoprazole/amoxicillin with omeprazole/amoxicillin for the eradication of Helicobacter pylori in patients with duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Smoking; Treatment Outcome | 1997 |
Age-dependent eradication of Helicobacter pylori with dual therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Age Factors; Aged; Amoxicillin; Anti-Ulcer Agents; Area Under Curve; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastric Acid; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Metabolic Clearance Rate; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors; Ranitidine | 1997 |
Triple therapy with lansoprazole, clarithromycin, and amoxicillin for the cure of Helicobacter pylori infection: a short report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 1996 |
Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Diarrhea; Double-Blind Method; Drug Eruptions; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Hypertension; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Prevalence; Proton Pump Inhibitors; Research Design; Treatment Outcome | 1996 |
Comparison of one or two weeks of lansoprazole, amoxicillin, and clarithromycin in the treatment of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Duodenitis; Esophagitis; Female; Helicobacter Infections; Helicobacter pylori; Hernia, Hiatal; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Smoking; Treatment Outcome | 1996 |
Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Metronidazole; Omeprazole; Penicillins; Placebos; Proton Pump Inhibitors; Ranitidine; Tetracycline | 1998 |
One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Antitrichomonal Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Single-Blind Method | 1997 |
Augmented eradication rates of Helicobacter pylori by new combination therapy with lansoprazole, amoxicillin, and rebamipide.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Alanine; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Antioxidants; Chemokines; Cytokines; Drug Therapy, Combination; Gastric Mucosa; Helicobacter Infections; Humans; Lansoprazole; Middle Aged; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Omeprazole; Penicillins; Peptic Ulcer; Prospective Studies; Proton Pump Inhibitors; Quinolones | 1998 |
Short duration therapy for Helicobacter pylori in Western Australia: the impact of metronidazole resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Penicillins; Tetracycline; Western Australia | 1998 |
Lansoprazole, amoxicillin, and clarithromycin triple therapy in vagotomized patients with dyspeptic complaints. A randomized, double-blind, placebo-controlled, clinical study without pretreatment diagnostic upper endoscopy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Recurrence; Vagotomy | 1998 |
Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Penicillins; Recurrence | 1998 |
Miconazole gel increases the cure rate of Helicobacter pylori infection when added to lansoprazole and amoxicillin in a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Gels; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Miconazole; Middle Aged; Omeprazole; Penicillins | 1998 |
Amount of Helicobacter pylori in gastric mucus during anti-H. pylori treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Polymerase Chain Reaction; Treatment Outcome | 1998 |
Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Stomach Ulcer | 1998 |
Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Developing Countries; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Pefloxacin; Proton Pump Inhibitors | 1998 |
Spiramycin as an alternative to amoxicillin treatment associated with lansoprazole/metronidazole for Helicobacter pylori infection in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Child; Child, Preschool; Drug Therapy, Combination; Gastrointestinal Agents; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Penicillins; Spiramycin | 1998 |
[Eradication therapies for Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Tinidazole | 1998 |
Factors influencing Helicobacter pylori eradication with 2 week combination therapy of lansoprazole and amoxycillin: intragastric distribution of colonization and gastric mucosal atrophy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastric Mucosa; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Proton Pump Inhibitors; Time Factors | 1998 |
Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Combined Modality Therapy; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors; Treatment Outcome | 1998 |
Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori infection: results of a prospective randomized open study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Stomach Ulcer | 1998 |
Effects of rebamipide in combination with lansoprazole and amoxicillin on Helicobacter pylori-infected gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alanine; Amoxicillin; Anti-Ulcer Agents; Diterpenes; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors; Quinolones; Stomach Ulcer; Treatment Outcome | 1998 |
Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Proton Pump Inhibitors; Treatment Outcome | 1998 |
Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Diterpenes; Drug Therapy, Combination; Female; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Hyperplasia; Immunoglobulin G; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Polyps; Proton Pump Inhibitors; Single-Blind Method; Statistics, Nonparametric; Stomach Neoplasms | 1998 |
Safety and efficacy of one-week triple therapy for eradicating Helicobacter pylori in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Child, Preschool; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Treatment Outcome | 1998 |
[Previous treatment with omeprazole and H. pylori: does it diminish the eradication efficacy of the "new" triple therapies of one week's duration?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Odds Ratio; Omeprazole; Penicillins; Prognosis; Prospective Studies; Time Factors | 1998 |
[Four kinds of new triple therapy regiments for Helicobacter pylori eradication in patients with peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Evaluation; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 1999 |
[A comparative study; one week treatment versus two weeks treatment with lansoprazol, amoxycillin and clarythromycin for the eradication of Helicobacter pylori in patient with gastric and duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Recurrence; Treatment Outcome | 1999 |
Efficacy of 1 week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Prospective Studies; Proton Pump Inhibitors; Time Factors | 1999 |
Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Carnosine; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Organometallic Compounds; Patient Compliance; Penicillins; Prospective Studies; Protective Agents; Zinc Compounds | 1999 |
The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Single-Blind Method; Treatment Outcome | 1999 |
Chronic idiopathic urticaria: natural course and association with Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Chronic Disease; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Urticaria | 1999 |
Efficacy of 7 day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Antibodies, Bacterial; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Treatment Outcome | 1999 |
Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and azithromycin: failure of a "promising" association.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Azithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Treatment Failure; Treatment Outcome | 1999 |
Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole | 1999 |
Short-term triple therapy with lansoprazole 30 mg or 60 mg, amoxycillin and clarithromycin to eradicate Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 1999 |
Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Ranitidine; Treatment Outcome | 1999 |
Eradication of Helicobacter pylori infection with proton pump-based triple therapy in patients in whom bismuth-based triple therapy failed.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Proton Pump Inhibitors; Salicylates; Treatment Outcome | 1999 |
Cost effectiveness of Helicobacter pylori eradication therapies in patients with duodenal ulcer. An analysis of triple therapy versus two dual therapy alternatives.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins | 1999 |
Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Esophagitis; Female; Food; Gastric Acid; Gastric Emptying; Gastric Mucosa; Gastrins; Gastritis; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Monitoring, Physiologic; Omeprazole; Penicillins; Polyethylene Glycols; Postprandial Period; Solvents | 1999 |
Eradication of Helicobacter pylori using 30 mg or 60 mg lansoprazole combined with amoxicillin and metronidazole: one and two weeks of a new triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Carbon Isotopes; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Time Factors; Treatment Outcome; Urea | 1999 |
Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Asia; Breath Tests; Clarithromycin; Double-Blind Method; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Risk Factors; Urea | 2000 |
Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection: comparison of 20 and 40 mg rabeprazole with 60 mg lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole | 2000 |
Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Combinations; Drug Resistance, Microbial; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Ornidazole; Penicillins; Peptic Ulcer; Treatment Outcome | 2000 |
A prospective trial of lansoprazole triple therapy for pediatric Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Biopsy; Child; Child, Preschool; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Digestive System; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Infant; Lansoprazole; Male; Omeprazole; Prospective Studies | 2000 |
Eradication of Helicobacter pylori with lansoprazole based triple therapy in peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Antitrichomonal Agents; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Thailand; Tinidazole; Treatment Outcome | 2000 |
Helicobacter pylori eradication with lansoprazole, amoxycillin and clarithromycin: testing an ideal regimen in a multicultural south east Asian population and examining factors potentially influencing eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; China; Clarithromycin; Drug Therapy, Combination; Ethnicity; Female; Helicobacter Infections; Helicobacter pylori; Humans; India; Lansoprazole; Likelihood Functions; Logistic Models; Malaysia; Male; Middle Aged; Omeprazole; Prospective Studies; Singapore | 2000 |
Comparison of seven and fourteen days of lansoprazole, clarithromycin, and amoxicillin therapy for eradication of Helicobacter pylori: a report from India.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; India; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins | 2000 |
[Treatment of Helicobacter pylori infection with lansoprazole 30 mg or 60 mg combined with two antibiotics for duodenal ulcers].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins | 2000 |
Comparison of the efficacy of 400mg and 800mg of clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection in a Japanese population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Omeprazole; Penicillins; Prospective Studies; Sensitivity and Specificity | 2000 |
Cure of Helicobacter pylori-positive active duodenal ulcer patients: a double-blind, multicentre, 12-month study comparing a two-week dual vs a one-week triple therapy. GISU (Interdisciplinary Group for Ulcer Study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Antitrichomonal Agents; Biopsy; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Digestive System; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors; Recurrence; Tinidazole | 2000 |
Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Omeprazole; Prospective Studies; Treatment Outcome | 2000 |
Does the depth of gastric ulceration influence a modified dual therapy with amoxicillin and lansoprazole for Helicobacter pylori-associated gastric ulcer?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Amoxicillin; Anti-Ulcer Agents; Diterpenes; Drug Therapy, Combination; Endosonography; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Pepsin A; Proton Pump Inhibitors; Stomach Ulcer; Time Factors; Wound Healing | 2000 |
High-dose ecabet sodium improves the eradication rate of helicobacter pylori in dual therapy with lansoprazole and amoxicillin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Diterpenes; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Single-Blind Method; Treatment Outcome | 2000 |
A short-term eradication therapy for Helicobacter pylori acute gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adolescent; Adult; Alanine; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Quinolones; Stomach; Time Factors | 2000 |
[Usefulness of new triple therapy containing PPI].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors | 2001 |
Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Logistic Models; Male; Middle Aged; Omeprazole; Prognosis; Prospective Studies; Proton Pump Inhibitors; Time Factors | 2001 |
Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Duodenal Ulcer; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Logistic Models; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Penicillins; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Treatment Outcome | 2001 |
Two weeks triple therapy with lansoprazole, amoxycillin and roxythromycin is better than dual therapy with lansoprazole and amoxycillin for H. pylori infection: a randomised, clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Penicillins; Roxithromycin | 2000 |
The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Organometallic Compounds; Patient Selection; Penicillins; Peptic Ulcer; Time Factors; Treatment Failure | 2001 |
Effect of Helicobacter pylori eradication on cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS) expression during gastric adaptation to aspirin (ASA) in humans.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blotting, Western; Clarithromycin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Electrophoresis, Polyacrylamide Gel; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Immunohistochemistry; Isoenzymes; Lansoprazole; Membrane Proteins; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Omeprazole; Prostaglandin-Endoperoxide Synthases | 2001 |
Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Analysis of Variance; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Female; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Recurrence; Treatment Outcome | 2001 |
Clarithromycin-based triple therapy for non-resistant Helicobacter pylori infection. How long should it be given?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Polymerase Chain Reaction; Time Factors | 2001 |
Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Carbon Isotopes; Clarithromycin; Diterpenes; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Pepsin A; Prospective Studies; Treatment Outcome; Urea; Urease | 2001 |
Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absenteeism; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Health Status; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Patient Satisfaction; Penicillins; Referral and Consultation | 2001 |
Prolonging proton pump inhibitor-based anti-Helicobacter pylori treatment from one to two weeks in duodenal ulcer: is it worthwhile?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Treatment Outcome | 2000 |
A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors | 2001 |
A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies | 1999 |
Ultrashort regimen of lansoprazole-amoxicillin-azithromycin for eradicating Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lebanon; Omeprazole; Penicillins; Research Design; Safety; Treatment Outcome | 2001 |
A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Microbial Sensitivity Tests; Middle Aged; Multicenter Studies as Topic; Omeprazole; Peptic Ulcer | 2001 |
Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Ranitidine; Regression Analysis; Treatment Outcome | 2002 |
Helicobacter pylori eradication with beta carotene, ascorbic acid and allicin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antioxidants; Ascorbic Acid; beta Carotene; Clarithromycin; Disulfides; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Sulfinic Acids | 2001 |
Therapeutic effects of antibacterial treatment for intractable skin diseases in Helicobacter pylori-positive Japanese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Child; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulin G; Lansoprazole; Male; Middle Aged; Omeprazole; Skin Diseases; Treatment Outcome | 2002 |
Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Costs; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Treatment Outcome | 2002 |
Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Taiwan | 2002 |
Amoxicillin/tetracycline combinations are inadequate as alternative therapies for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Doxycycline; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Ranitidine; Tetracycline; Treatment Failure | 2002 |
[Triple therapy with faropenem, proton pump inhibitor (PPI), and amoxicillin for clarithromycin-resistant H. pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; beta-Lactams; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lactams; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 2002 |
Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Female; Gastroesophageal Reflux; Helicobacter Infections; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Quality of Life; Urea | 2002 |
Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Pronase; Treatment Outcome | 2002 |
Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; DNA; Drug Therapy, Combination; Enzyme Inhibitors; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Peptic Ulcer; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome | 2002 |
Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Hydrocortisone; Lansoprazole; Liver Function Tests; Male; Middle Aged; Omeprazole; Oxidoreductases, N-Demethylating; Penicillins; Protein Synthesis Inhibitors | 2002 |
Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Bifidobacterium; Clarithromycin; Combined Modality Therapy; Drug Therapy, Combination; Feces; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lactobacillus; Lansoprazole; Male; Middle Aged; Omeprazole; Patient Compliance; Probiotics; Yogurt | 2002 |
Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Stomach Ulcer | 2002 |
Vitamin C and E supplements to lansoprazole-amoxicillin-metronidazole triple therapy may reduce the eradication rate of metronidazole-susceptible Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Ascorbic Acid; Dietary Supplements; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Inflammation; Lansoprazole; Male; Metronidazole; Omeprazole; Severity of Illness Index; Stomach Diseases; Treatment Outcome; Vitamin E | 2002 |
Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Area Under Curve; Clarithromycin; Confidence Intervals; Cross-Over Studies; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Humans; Lansoprazole; Male; Omeprazole | 2002 |
The effects of nocturnal acid breakthrough on Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Circadian Rhythm; Clarithromycin; Drug Therapy, Combination; Female; Gastric Acid; Gastric Acidity Determination; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Treatment Outcome | 2002 |
Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Cytochrome P-450 Enzyme System; Drug Resistance; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Rabeprazole; Treatment Outcome | 2003 |
Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Logistic Models; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Peptic Ulcer; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Treatment Failure; Treatment Outcome | 2003 |
[New triple therapy for Helicobacter pylori infection in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole | 2003 |
Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Penicillins; Piperidines; Prospective Studies; Pyridines | 2003 |
Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome | 2003 |
The selection of triple therapy for Helicobacter pylori eradication in chronic renal insufficiency.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Kidney Failure, Chronic; Lansoprazole; Male; Middle Aged; Omeprazole; Treatment Outcome | 2003 |
Density of Helicobacter pylori may affect the efficacy of eradication therapy and ulcer healing in patients with active duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Colony Count, Microbial; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Patient Compliance; Penicillins; Wound Healing | 2003 |
Helicobacter pylori eradication therapy for the remnant stomach after gastrectomy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Biomarkers; Biopsy; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Gastrectomy; Gastric Stump; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Lansoprazole; Male; Middle Aged; Omeprazole; Pepsinogen A; Pepsinogen C; Proton Pump Inhibitors; Proton Pumps; Randomized Controlled Trials as Topic; Severity of Illness Index; Time Factors; Treatment Outcome | 2003 |
Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Treatment Outcome | 2003 |
Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Clarithromycin; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Probability; Reference Values; Severity of Illness Index; Treatment Outcome | 2003 |
One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Salicylates; Severity of Illness Index; Treatment Outcome | 2003 |
Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clarithromycin; Dyspepsia; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Patient Compliance; Peptic Ulcer; Secondary Prevention; Treatment Outcome | 2003 |
Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Interleukin-1; Lansoprazole; Logistic Models; Male; Middle Aged; Mixed Function Oxygenases; Multivariate Analysis; Omeprazole; Polymorphism, Genetic; Probability; Proton Pump Inhibitors; Proton Pumps; Rabeprazole; Statistics, Nonparametric; Treatment Outcome | 2003 |
Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antibody Specificity; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Gastritis; Genetic Predisposition to Disease; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Interleukin-1; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Mutation; Omeprazole; Patient Compliance; Peptic Ulcer; Polymorphism, Genetic; Proton Pump Inhibitors; Proton Pumps; Treatment Outcome | 2004 |
[Eradication effect of lansoprazole-based triple therapy against H. pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Neoplasms; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Stomach Ulcer | 2004 |
Rank order of success favors longer duration of imidazole-based therapy for Helicobacter pylori in duodenal ulcer disease: a randomized pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Imidazoles; Lansoprazole; Male; Middle Aged; Omeprazole; Pilot Projects; Prospective Studies; Time Factors; Tinidazole; Urea | 2004 |
Helicobacter pylori eradication: efficacy of conventional therapy in India.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastrointestinal Agents; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Polymerase Chain Reaction; Tinidazole; Treatment Outcome | 2004 |
Use of imidazole-based eradication regimens for Helicobacter pylori should be abandoned in North India regardless of in vitro antibiotic sensitivity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Helicobacter Infections; Helicobacter pylori; Humans; India; Lansoprazole; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Peptic Ulcer; Prospective Studies; Tinidazole; Treatment Outcome; Wound Healing | 2004 |
Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 2004 |
In treatment of active duodenal ulcer and Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides; Treatment Outcome | 2003 |
Dual vs. triple therapy for childhood Helicobacter pylori gastritis: a double-blind randomized multicentre trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Breath Tests; Child; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Recurrence; Tinidazole; Urea | 2004 |
Helicobacter pylori eradication decreases blood neutrophil and monocyte counts.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Leukocyte Count; Leukocytes, Mononuclear; Male; Middle Aged; Neutrophils; Omeprazole; Peptic Ulcer; Retrospective Studies | 2004 |
The effect of Helicobacter pylori eradication on gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Endoscopes, Gastrointestinal; Female; Gastroesophageal Reflux; Heartburn; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Monitoring, Physiologic; Omeprazole; Treatment Outcome; Urease | 2004 |
Comparison of the efficacy of 250 mg and 500 mg clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Patient Care Management; Treatment Outcome | 2004 |
Effect of Helicobacter pylori eradication on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Omeprazole; Platelet Count; Purpura, Thrombocytopenic, Idiopathic | 2004 |
Effects of killing Helicobacter pylori quadruple therapy on peptic ulcer: a randomized double-blind clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Prospective Studies; Recurrence; Wound Healing | 2005 |
First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Multivariate Analysis; Omeprazole; Ranitidine; Risk Factors | 2005 |
Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Esophagitis, Peptic; Follow-Up Studies; Heartburn; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Middle Aged; Omeprazole; Risk Assessment; Single-Blind Method | 2005 |
Quality of gastric ulcer healing evaluated by endoscopic ultrasonography.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Endosonography; Female; Helicobacter Infections; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Stomach Ulcer; Wound Healing | 2005 |
Randomized study of Helicobacter pylori eradication therapy and proton pump inhibitor monotherapy for idiopathic thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Purpura, Thrombocytopenic, Idiopathic; Remission Induction; Treatment Outcome | 2005 |
A follow-up study on the effect of Helicobacter pylori eradication on the severity of gastric histology.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Atrophy; Female; Follow-Up Studies; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Intestines; Lansoprazole; Male; Metaplasia; Metronidazole; Middle Aged; Omeprazole; Severity of Illness Index; Stomach; Treatment Outcome | 2005 |
A randomized trial of triple therapy for pediatric Helicobacter pylori infection and risk factors for treatment failure in a population with a high prevalence of infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Child; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Omeprazole; Prevalence; Prospective Studies; Risk Factors; Treatment Failure | 2005 |
Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Single-Blind Method; Sulfoxides; Treatment Outcome | 2004 |
[H. pylori eradication package set (Lansap)].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Packaging; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Patient Compliance; Proton Pump Inhibitors; Surveys and Questionnaires; Treatment Outcome | 2005 |
[PPI plus bismuth-based quintuple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Minocycline; Omeprazole; Patient Compliance; Proton Pump Inhibitors; Treatment Outcome | 2005 |
[Cetraxate hydrochloride (Neuer) induces the effectiveness of new triple therapy in H. pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Tranexamic Acid; Treatment Outcome | 2005 |
Should we eradicate Helicobacter pylori before prescribing an NSAID? Result of a placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Needs Assessment; Omeprazole; Peptic Ulcer; Probability; Reference Values; Rheumatic Diseases; Risk Assessment; Statistics, Nonparametric; Treatment Outcome | 2005 |
Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Biopsy; Brazil; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prevalence; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2006 |
Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Hong Kong; Humans; Lansoprazole; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Omeprazole; Organometallic Compounds; Tetracycline; Treatment Outcome | 2006 |
Design and planned analyses of an ongoing randomized trial assessing the preventive effect of Helicobacter pylori eradication on occurrence of new gastric carcinomas after endoscopic resection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Clinical Protocols; Combined Modality Therapy; Endoscopy; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Lansoprazole; Middle Aged; Omeprazole; Proportional Hazards Models; Research Design; Sample Size; Stomach Neoplasms | 2006 |
A pilot study to evaluate a new combination therapy for gastric ulcer: Helicobacter pylori eradication therapy followed by gastroprotective treatment with rebamipide.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Alanine; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Therapy, Combination; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Middle Aged; Pilot Projects; Quinolones; Stomach Ulcer; Treatment Outcome | 2006 |
Eradication of H pylori infection in a rural population: one-day quadruple therapy versus 7-day triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Pilot Projects; Prospective Studies; Rural Population | 2006 |
Helicobacter pylori eradication versus prokinetics in the treatment of functional dyspepsia: a randomized, double-blind study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Cisapride; Clarithromycin; Domperidone; Dopamine Antagonists; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Female; Gastrointestinal Agents; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Treatment Outcome | 2006 |
Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Famotidine; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Metronidazole; Middle Aged; Proton Pump Inhibitors; Proton Pumps; Treatment Failure | 2006 |
Pharmacoeconomic comparison of Helicobacter pylori eradication regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Infective Agents; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Economics, Pharmaceutical; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Melena; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Prospective Studies; Ranitidine; Taste Disorders; Time Factors; Treatment Outcome | 2006 |
Effects of anti-Helicobacter pylori treatment and probiotic supplementation on intestinal microbiota.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bifidobacterium; Cell Count; Clarithromycin; Combined Modality Therapy; Double-Blind Method; Feces; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intestines; Lacticaseibacillus rhamnosus; Lansoprazole; Male; Middle Aged; Probiotics; Propionibacterium; Treatment Outcome | 2007 |
Duration of the metronidazole-containing regimen for eradication of Helicobacter pylori infection in northern Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Time Factors | 2006 |
Eradication of Helicobacter pylori in hemodialysis patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Kidney Failure, Chronic; Lansoprazole; Male; Middle Aged; Renal Dialysis | 2007 |
Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Omeprazole; Phenotype; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Retreatment; Stomach Diseases; Treatment Outcome | 2007 |
Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Organometallic Compounds; Proton Pump Inhibitors; Tetracycline; Treatment Failure; Treatment Outcome; Turkey | 2008 |
Improvement in symptoms after H2-receptor antagonist-based therapy for eradication of H pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Adult; Aged; Amoxicillin; Anti-Infective Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Piperidines; Pyridines | 2007 |
Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Nausea; Probiotics; Prospective Studies; Saccharomyces; Stomach Diseases; Treatment Outcome | 2007 |
Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Female; Gastric Acid; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Treatment Outcome | 2007 |
Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Constipation; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Nausea; Ofloxacin; Treatment Outcome; Vomiting | 2007 |
Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alanine; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Female; Follow-Up Studies; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Middle Aged; Prevalence; Proton Pump Inhibitors; Quinolones; Retrospective Studies; Stomach Ulcer; Treatment Outcome | 2007 |
The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Middle Aged; Single-Blind Method; Statistics, Nonparametric; Tetracycline; Treatment Outcome | 2007 |
Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Retreatment; Treatment Outcome | 2008 |
Treatment of Helicobacter pylori in surgical practice: a randomised trial of triple versus quadruple therapy in a rural district general hospital.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Hospitals, General; Hospitals, Rural; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Organometallic Compounds; Patient Compliance; Prospective Studies; Tetracycline; Treatment Outcome | 2008 |
Helicobacter pylori eradication in long-term proton pump inhibitor users is highly cost-effective: economic analysis of the HELPUP trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cost-Benefit Analysis; Double-Blind Method; Drug Costs; Dyspepsia; Follow-Up Studies; Health Care Costs; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Proton Pump Inhibitors; Quality of Life; Treatment Outcome; United Kingdom | 2008 |
Long-term efficacy of Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura: 7-year follow-up prospective study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adrenal Cortex Hormones; Adult; Aged; Amoxicillin; Clarithromycin; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Platelet Count; Prospective Studies; Purpura, Thrombocytopenic, Idiopathic; Remission Induction; Time Factors; Treatment Outcome | 2009 |
Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Korea; Lansoprazole; Male; Middle Aged; Piperidines; Pyridines; Time Factors; Treatment Outcome | 2008 |
Evaluation of two triple-therapy regimens with metronidazole or clarithromycin for the eradication of H. pylori infection in Vietnamese children: a randomized, double-blind clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Antigens, Bacterial; Child; Child, Preschool; Clarithromycin; Double-Blind Method; Feces; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Stomach; Vietnam | 2008 |
Helicobacter pylori eradication therapy may facilitate gastric ulcer healing after endoscopic mucosal resection: a prospective randomized study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Iatrogenic Disease; Lansoprazole; Male; Middle Aged; Prospective Studies; Severity of Illness Index; Stomach Neoplasms; Stomach Ulcer; Treatment Outcome | 2008 |
High efficacy of bismuth subcitrate for Helicobacter pylori eradication in pangastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Organometallic Compounds; Proton Pump Inhibitors; Young Adult | 2009 |
Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Prospective Studies; Tetracycline; Treatment Outcome; Young Adult | 2009 |
Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Female; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Stomach Neoplasms; Young Adult | 2009 |
Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Lansoprazole; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Treatment Outcome | 2010 |
Does pretreatment with lansoprazole influence Helicobacter pylori eradication rate and quality of life?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Amoxicillin; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Logistic Models; Male; Middle Aged; Proton Pump Inhibitors; Quality of Life; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Stomach Ulcer; Treatment Outcome | 2010 |
Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Breath Tests; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Middle Aged; Ofloxacin | 2010 |
Kefir improves the efficacy and tolerability of triple therapy in eradicating Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Cultured Milk Products; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged | 2011 |
Helicobacter pylori eradication lowers serum asymmetric dimethylarginine levels.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Arginine; Atherosclerosis; Cardiovascular Abnormalities; Clarithromycin; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Nitric Oxide Synthase Type III; Young Adult | 2010 |
Comparison of two different treatment protocols in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Tetracycline; Turkey | 2011 |
Triple therapy with ecabet sodium, amoxicillin and lansoprazole for 2 weeks as the rescue regimen for H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Treatment Failure | 2011 |
A new modified concomitant therapy for Helicobacter pylori eradication in Turkey.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Treatment Outcome; Young Adult | 2011 |
Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Republic of Korea; Treatment Outcome | 2012 |
Supplementing vitamins C and E to standard triple therapy for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Ascorbic Acid; Clarithromycin; Combined Modality Therapy; Dietary Supplements; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Lansoprazole; Male; Middle Aged; Outpatient Clinics, Hospital; Proton Pump Inhibitors; Turkey; Vitamin E | 2012 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Latin America; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Time Factors; Treatment Outcome; Urea | 2011 |
A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Doxycycline; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Lansoprazole; Levofloxacin; Male; Middle Aged; Nitro Compounds; Ofloxacin; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Recurrence; Thiazoles; Young Adult | 2011 |
Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Prospective Studies; Treatment Outcome | 2012 |
Comparative study of Helicobacter pylori eradication rates with 5-day quadruple "concomitant" therapy and 7-day standard triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Algorithms; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Medication Adherence; Metronidazole; Middle Aged; Prospective Studies; Treatment Outcome | 2013 |
Eradication of Helicobacter pylori in children in Vietnam in relation to antibiotic resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Bacterial Agents; Child; Child, Preschool; Clarithromycin; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Vietnam | 2012 |
Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Chi-Square Distribution; Clarithromycin; Confidence Intervals; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Lansoprazole; Male; Metronidazole; Middle Aged; Patient Compliance; Republic of Korea; Urea | 2012 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Ofloxacin | 2013 |
Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan.
Topics: Aged; Amoxicillin; Anti-Ulcer Agents; Drug Resistance; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Levofloxacin; Male; Middle Aged; Treatment Outcome | 2013 |
Helicobacter pylori eradication on iatrogenic ulcer by endoscopic resection of gastric tumour: a prospective, randomized, placebo-controlled multi-centre trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Endoscopy; Female; Helicobacter Infections; Helicobacter pylori; Humans; Iatrogenic Disease; Lansoprazole; Male; Middle Aged; Prospective Studies; Stomach Neoplasms; Stomach Ulcer; Treatment Outcome | 2013 |
Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Helicobacter Infections; Humans; Lansoprazole; Latin America; Male; Medication Adherence; Metronidazole; Middle Aged; Primary Prevention; Recurrence; Risk; Stomach Neoplasms; Young Adult | 2013 |
[Is sequential eradication of Helicobacter pylori effective? Sequential treatment more effective than triple therapy in patients with clarithromycin resistance].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Peptic Ulcer; Stomach Neoplasms; Taiwan | 2013 |
Antibiotic treatment decreases microbial burden associated with pseudomyxoma peritonei and affects β-catenin distribution.
Topics: Adenocarcinoma, Mucinous; Amoxicillin; Anti-Bacterial Agents; Bacterial Load; beta Catenin; Cell Membrane; Cell Nucleus; Clarithromycin; Combined Modality Therapy; Helicobacter Infections; Helicobacter pylori; Humans; In Situ Hybridization; Lansoprazole; Middle Aged; Peritoneal Neoplasms; Protein Transport; Pseudomyxoma Peritonei; Treatment Outcome | 2013 |
Randomized trial comparing rabeprazole- versus lansoprazole-based Helicobacter pylori eradication regimens.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenoscopy; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole | 2013 |
The efficacy of two-week quadruple first-line therapy with bismuth, lansoprazole, amoxicillin, clarithromycin on Helicobacter pylori eradication: a prospective study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Prospective Studies; Young Adult | 2013 |
A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Endoscopy, Digestive System; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Ranitidine; Treatment Outcome; Young Adult | 2013 |
Nickel free-diet enhances the Helicobacter pylori eradication rate: a pilot study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Contraindications; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Nickel; Pilot Projects | 2014 |
Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Medication Adherence; Metronidazole; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2014 |
The effect of Helicobacter pylori eradication on insulin resistance and HbA1c level in people with normal glucose levels: a prospective study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Blood Glucose; Clarithromycin; Drug Therapy, Combination; Female; Glycated Hemoglobin; Helicobacter Infections; Helicobacter pylori; Homeostasis; Humans; Insulin Resistance; Lansoprazole; Male; Prospective Studies; Single-Blind Method | 2015 |
A randomised clinical trial of 10-day concomitant therapy and standard triple therapy for Helicobacter pylori eradication.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chi-Square Distribution; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Logistic Models; Male; Metronidazole; Middle Aged; Multivariate Analysis; Prospective Studies; Republic of Korea; Time Factors; Treatment Outcome | 2014 |
Sequential therapy versus standard triple therapy for Helicobacter pylori eradication in children: any advantage in clarithromycin-resistant strains?
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Child; Child, Preschool; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Medication Adherence; Metronidazole; Treatment Outcome | 2014 |
Efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenia patients with moderate thrombocytopenia.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia; Treatment Outcome; Young Adult | 2015 |
Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Organometallic Compounds; Probiotics; Prognosis; Prospective Studies; Salicylates; Thailand | 2014 |
Comparison of levofloxacin- and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2014 |
Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial.
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Biopsy, Needle; Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Immunohistochemistry; Lansoprazole; Levofloxacin; Male; Metronidazole; Middle Aged; Prospective Studies; Treatment Failure; Treatment Outcome; Young Adult | 2015 |
Comparison of standard and standard plus vitamin E therapy for Helicobacter pylori eradications in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Antioxidants; Breath Tests; Child; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Prospective Studies; Proton Pump Inhibitors; Vitamin E | 2014 |
Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bifidobacterium; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lacticaseibacillus rhamnosus; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Pantoprazole; Placebos; Probiotics; Prospective Studies; Proton Pump Inhibitors; Surveys and Questionnaires; Treatment Outcome | 2015 |
Preoperative vs Postoperative Eradication of Helicobacter pylori in 150 Patients with Gastric Cancer: A Randomized Controlled Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastrectomy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Postoperative Care; Preoperative Care; Proton Pump Inhibitors; Stomach Neoplasms; Treatment Outcome | 2015 |
Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Young Adult | 2015 |
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of
Topics: Adult; Ambulatory Care; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Hospitalization; Humans; Lansoprazole; Male; Metronidazole; Proton Pump Inhibitors; Treatment Outcome | 2016 |
The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; DNA, Ribosomal; Drug Therapy, Combination; Female; Gastritis; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; High-Throughput Nucleotide Sequencing; Humans; Lansoprazole; Male; Middle Aged; Peptic Ulcer; Probiotics; Proton Pump Inhibitors; Sequence Analysis, DNA; Stomach Neoplasms | 2016 |
Outcome evaluation of clarithromycin, metronidazole and lansoprazole regimens in Helicobacter pylori positive or negative children with resistant otitis media with effusion.
Topics: Amoxicillin; Anti-Bacterial Agents; Antigens, Bacterial; Case-Control Studies; Child; Child, Preschool; Chronic Disease; Clarithromycin; Clavulanic Acid; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Otitis Media with Effusion; Proton Pump Inhibitors; Treatment Outcome | 2015 |
Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori: A Randomized Trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Metronidazole; Middle Aged; Stomach Diseases; Treatment Outcome | 2016 |
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2016 |
Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Medication Adherence; Metronidazole; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Tetracycline; Treatment Failure; Treatment Outcome; Young Adult | 2016 |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Organometallic Compounds; Proton Pump Inhibitors; Taiwan; Tetracycline; Urea | 2016 |
Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Single-Blind Method; Sulfonamides; Treatment Outcome | 2017 |
Improving the standard sequential treatment of Helicobacter pylori with either extended treatment or by adding bismuth.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors | 2017 |
Concomitant, sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection in Korea: study protocol for a randomized controlled trial.
Topics: Amoxicillin; Clarithromycin; Clinical Protocols; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Sample Size | 2017 |
Can probiotics improve efficiency and safety profile of triple Helicobacter pylori eradication therapy? A prospective randomized study.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Biopsy; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Probiotics; Prospective Studies; Proton Pump Inhibitors; Serbia; Time Factors; Treatment Outcome; Young Adult | 2016 |
A Prospective, randomized study comparing 7-day and 14-day quadruple therapies as first-line treatments for helicobacter pylori infection in patients with functional dyspepsia.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Antidiarrheals; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Salicylates | 2018 |
Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Dizziness; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Nausea; Patient Compliance; Prospective Studies; Proton Pump Inhibitors; Time Factors; Treatment Outcome | 2018 |
Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Gastritis; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Sulfonamides; Treatment Failure; Treatment Outcome | 2019 |
Comparison between daily single-dose triple therapy and conventional triple therapy on patient compliance and Helicobacter pylori eradication: A randomized controlled trial.
Topics: Adult; Amoxicillin; Clarithromycin; Dysgeusia; Esomeprazole; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Patient Compliance; Tinidazole; Treatment Failure; Treatment Outcome; Young Adult | 2018 |
Intraluminal therapy for Helicobacter pylori infection.
Topics: Acetylcysteine; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Expectorants; Female; Gastric Acid; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Metronidazole; Middle Aged; Powders; Prospective Studies; Proton Pump Inhibitors; Remission Induction; Therapeutic Irrigation; Time Factors; Treatment Outcome; Young Adult | 2019 |
Twice daily short-message-based re-education could improve Helicobacter pylori eradication rate in young population: A prospective randomized controlled study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Disease Eradication; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Patient Education as Topic; Pectins; Prospective Studies; Text Messaging; Young Adult | 2019 |
Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Disease Eradication; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Medication Adherence; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Republic of Korea; Treatment Outcome | 2019 |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Body Mass Index; Clarithromycin; Disease Eradication; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Escherichia coli; Female; Follow-Up Studies; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metabolic Syndrome; Metronidazole; Middle Aged; Organometallic Compounds; Prevalence; Tetracycline | 2019 |
Helicobacter pylori Eradication Regressed Gastric Hyperplastic Polyp: A Randomized Controlled Trial.
Topics: Adenomatous Polyps; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Monitoring; Endoscopy, Digestive System; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Outcome Assessment, Health Care; Proton Pump Inhibitors; Stomach Neoplasms | 2020 |
Family History of Gastric Cancer and
Topics: Adenoma; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Kaplan-Meier Estimate; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Republic of Korea; Stomach Neoplasms | 2020 |
Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Pyrroles; Sulfonamides; Treatment Outcome | 2022 |
Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients.
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Neoplasm Recurrence, Local; Pyrroles; Sulfonamides | 2022 |
Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome; United States | 2022 |
179 other study(ies) available for lansoprazole and amoxicillin
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Helicobacter heilmannii: new spiral shaped bacterium that may be responsible for ulcerated gastritis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Gastritis; Helicobacter; Helicobacter Infections; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Stomach Ulcer; Tinidazole | 1995 |
Proton-pump inhibitor-refractory gastric ulcer and Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Ranitidine; Stomach Ulcer | 1993 |
Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Duodenoscopy; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Pilot Projects; Treatment Outcome | 1995 |
Short-term low-dose triple therapy with lansoprazole plus amoxycillin and clarithromycin for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole | 1996 |
Effect of lansoprazole in mono-, dual-, or triple therapy on Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Penicillins; Proton Pump Inhibitors; Stomach Ulcer; Tinidazole | 1996 |
Endoscopic topical therapy for the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Topical; Amoxicillin; Antacids; Anti-Ulcer Agents; Bismuth; Drug Combinations; Drug Therapy, Combination; Dyspepsia; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Instillation, Drug; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Pronase | 1996 |
Eradication of Helicobacter pylori followed by reinfection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Blotting, Southern; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Penicillins; Peptic Ulcer; Polymorphism, Restriction Fragment Length; Proton Pump Inhibitors; Recurrence | 1996 |
[Erradicating treatment of Helicobacter pylori with lansoprazole and amoxicillin in duodenal ulcer patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Prospective Studies | 1996 |
Percentage changes in serum pepsinogens are useful as indices of eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Pepsinogens; Stomach Ulcer | 1997 |
Eradication of Helicobacter pylori in patients with end-stage renal disease under dialysis treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Combined Modality Therapy; Diterpenes; Drug Evaluation; Drug Therapy, Combination; Fatty Alcohols; Female; Helicobacter Infections; Helicobacter pylori; Humans; Kidney Failure, Chronic; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Renal Dialysis; Time Factors | 1997 |
[A case of gastric MALT lymphoma regressed endoscopically and pathologically after eradication of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Male; Omeprazole; Stomach Neoplasms | 1997 |
Resolution of protein-losing hypertrophic gastropathy by eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child, Preschool; Drug Therapy, Combination; Gastric Mucosa; Gastritis, Hypertrophic; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Omeprazole; Penicillins; Protein-Losing Enteropathies | 1997 |
Susceptibility of Helicobacter pylori isolates against agents commonly administered for eradication therapy and the efficacy of chemotherapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole | 1997 |
Bactericidal activity and synergy studies of proton pump inhibitors and antibiotics against Helicobacter pylori in vitro.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Synergism; Enzyme Inhibitors; Erythromycin; Helicobacter pylori; Lansoprazole; Microbial Sensitivity Tests; Omeprazole; Proton Pump Inhibitors | 1997 |
Gastric metaplasia and Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Duodenal Ulcer; Female; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Metaplasia; Metronidazole; Middle Aged; Omeprazole; Penicillins; Stomach; Treatment Outcome | 1997 |
Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxycillin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole | 1997 |
Pharmacological therapy of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Costs; Drug Resistance, Microbial; Drug Therapy, Combination; Guidelines as Topic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Patient Compliance; Penicillins; Proton Pump Inhibitors; Tetracycline; Treatment Outcome; Vaccination | 1997 |
[Two step therapy for education of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors | 1997 |
H. pylori eradication by LAC.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Food-Drug Interactions; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole | 1997 |
Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin, and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Pilot Projects; Tetracycline; Treatment Outcome | 1996 |
Treatment of Helicobacter pylori infection: summary of a meeting at the Fourth United European Gastroenterology Week, September 20, 1995.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Enzyme Inhibitors; Europe; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Tetracycline; Tinidazole | 1996 |
Disappearance of multiple hyperplastic polyps after the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Hyperplasia; Lansoprazole; Middle Aged; Omeprazole; Stomach; Time Factors | 1997 |
Interaction of drugs for eradication therapy against antibiotic-resistant strains of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Colony Count, Microbial; Drug Resistance, Microbial; Drug Synergism; Helicobacter Infections; Helicobacter pylori; Lansoprazole; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Penicillins | 1997 |
[Gastric lymphoma--a case report].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Diterpenes; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Male; Omeprazole; Penicillins; Stomach; Stomach Neoplasms | 1998 |
Enhancement of neutrophil infiltration in the corpus after failure of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Drug Therapy, Combination; Duodenal Ulcer; Famotidine; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Interleukin-8; Lansoprazole; Male; Middle Aged; Neutrophils; Omeprazole; Peroxidase; Proton Pump Inhibitors; Stomach Ulcer | 1997 |
Effect of Helicobacter pylori infection on gastric juice pH.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ammonia; Amoxicillin; Anti-Ulcer Agents; Case-Control Studies; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Acid; Gastric Juice; Gastric Mucosa; Gastrins; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors; Stomach Ulcer | 1998 |
[Sensitivity of Helicobacter pylori to amoxicillin and clarythromycin with special reference to eradication therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microbial; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Penicillin Resistance; Penicillins; Peptic Ulcer | 1998 |
Effect of metronidazole resistance on bacterial eradication of Helicobacter pylori in infected children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Child; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Omeprazole; Prospective Studies; Spiramycin | 1998 |
Analysis of the 13C-urea breath test for detection of Helicobacter pylori infection based on the kinetics of delta-13CO2 using laser spectroscopy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Predictive Value of Tests; Proton Pump Inhibitors; Sensitivity and Specificity; Spectrum Analysis; Urea | 1998 |
Treating Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Combinations; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Organometallic Compounds; Penicillins; Peptic Ulcer; Ranitidine | 1998 |
Relationship between the eradication of Helicobacter pylori and the healing pattern of peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Recurrence; Stomach Ulcer; Treatment Outcome; Wound Healing | 1998 |
Gastric urease activity is inversely associated with the success of treatment for Helicobacter pylori: effect of sofalcone.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Breath Tests; Carbon Isotopes; Chalcone; Chalcones; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors; Stomach Ulcer; Treatment Outcome; Urea; Urease | 1998 |
Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Drug Resistance, Microbial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Peptic Ulcer; Prospective Studies | 1999 |
Relapse of duodenal ulcers after successful eradication of Helicobacter pylori in gastric ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Recurrence; Stomach Ulcer | 1999 |
Endoscopic and histological reversibility of gastric adenoma after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenoma; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diagnosis, Differential; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Precancerous Conditions; Stomach Neoplasms | 1999 |
Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Lansoprazole; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Proton Pump Inhibitors | 2000 |
[Does eliminating Helicobacter pylori mean the healing of the duodenal ulcer? The results of a prospective study in Spain].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Prognosis; Prospective Studies; Remission Induction; Spain | 2000 |
Mucosal change of the stomach with low-grade mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: follow-up study of 48 cases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Male; Metronidazole; Middle Aged; Omeprazole; Reverse Transcriptase Polymerase Chain Reaction; Stomach; Stomach Neoplasms | 2000 |
Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Creatinine; Female; Helicobacter Infections; Helicobacter pylori; Humans; Kidney; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Ranitidine | 2000 |
Helicobacter acinonychis eradication leading to the resolution of gastric lesions in tigers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Carnivora; Clarithromycin; DNA, Bacterial; Drug Therapy, Combination; Endoscopy; Female; Helicobacter; Helicobacter Infections; Lansoprazole; Male; Omeprazole; Penicillins; Polymerase Chain Reaction; Stomach; Stomach Ulcer | 2000 |
Treatment of Helicobacter pylori infection: is less more?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Pantoprazole; Penicillins; Proton Pump Inhibitors; Sulfoxides; Time Factors | 2000 |
Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Pilot Projects; Rifabutin; Treatment Failure | 2000 |
Endoscopic characteristics of low-grade gastric mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; B-Lymphocytes; Base Sequence; Biopsy; Clone Cells; Data Interpretation, Statistical; DNA, Complementary; DNA, Neoplasm; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Male; Metronidazole; Middle Aged; Molecular Sequence Data; Omeprazole; Penicillins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Time Factors | 2000 |
Helicobacter pylori infection in renal transplant recipients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Immunosuppressive Agents; Kidney Transplantation; Lansoprazole; Male; Middle Aged; Omeprazole; Postoperative Complications; Proton Pump Inhibitors; Time Factors | 2000 |
Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Omeprazole; Penicillins; Prospective Studies; Remission Induction; Stomach Neoplasms | 2001 |
Early stage gastric MALT lymphoma with high-grade component cured by Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Omeprazole; Proton Pump Inhibitors; Remission Induction; Stomach Neoplasms | 2001 |
A case of gastric plasmacytoma associated with Helicobacter pylori infection: improvement of abnormal endoscopic and EUS findings after H. pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Biopsy, Needle; Clarithromycin; Drug Therapy, Combination; Endosonography; Follow-Up Studies; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Plasmacytoma; Stomach Neoplasms; Treatment Outcome | 2001 |
Effects of lansoprazole, clarithromycin and pH gradient on uptake of [14C]amoxycillin into rat gastric tissue.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Ulcer Agents; Biological Transport; Clarithromycin; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Duodenum; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Hydrogen-Ion Concentration; Lansoprazole; Male; Omeprazole; Penicillins; Peptic Ulcer; Rats; Rats, Wistar | 2001 |
Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Recurrence; Retrospective Studies; Treatment Failure | 2001 |
Regression of primary lymphoma of the ampulla of Vater after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Ampulla of Vater; Biopsy; Clarithromycin; Common Bile Duct Neoplasms; Drug Therapy, Combination; Duodenal Neoplasms; Endosonography; Follow-Up Studies; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Mucosa; Lansoprazole; Lymphoma, Follicular; Male; Middle Aged; Omeprazole | 2001 |
Pseudomembranous colitis without diarrhoea following Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diarrhea; Enterocolitis, Pseudomembranous; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Occult Blood; Omeprazole; Penicillins | 2001 |
Resolution of Ménétrier's disease after Helicobacter pylori eradicating therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Gastritis, Hypertrophic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Treatment Outcome | 2001 |
Noninvasive Helicobacter pylori testing for the "test-and-treat" strategy: a decision analysis to assess the effect of past infection on test choice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antibodies, Bacterial; Antigens, Bacterial; Breath Tests; Clarithromycin; Cohort Studies; Costs and Cost Analysis; Decision Support Techniques; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Predictive Value of Tests; Recurrence; Unnecessary Procedures | 2001 |
Evaluation of the cost-effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Duodenal Ulcer; Health Care Costs; Helicobacter Infections; Humans; Lansoprazole; Markov Chains; Omeprazole; Penicillins; Stomach Ulcer; Treatment Outcome | 2001 |
Effects of lansoprazole and amoxicillin on uptake of [(14)C]clarithromycin into gastric tissue in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Interactions; Duodenum; Gastric Mucosa; Gastrointestinal Contents; In Vitro Techniques; Injections, Intravenous; Lansoprazole; Male; Omeprazole; Penicillins; Rats; Rats, Wistar; Stomach; Tissue Distribution | 2001 |
Localization of [14C]amoxicillin in rat gastric tissue when administered with lansoprazole and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Carbon Radioisotopes; Clarithromycin; Drug Therapy, Combination; Gastric Mucosa; Lansoprazole; Male; Omeprazole; Penicillins; Rats; Rats, Wistar | 2001 |
Fine-needle aspiration biopsy of an intra-abdominal inflammatory mass secondary to a penetrating duodenal ulcer mimicking neoplasm.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Biopsy, Needle; Clarithromycin; Diagnosis, Differential; Duodenal Ulcer; Duodenitis; Duodenum; Endoscopy, Digestive System; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2001 |
Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies | 2002 |
[Successful treatment of refractory idiopathic thrombocytopenic purpura by eradication of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Middle Aged; Omeprazole; Penicillins; Purpura, Thrombocytopenic, Idiopathic | 2001 |
The effect of Helicobacter pylori eradication on the natural course of atrophic gastritis with dysplasia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Combinations; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Serologic Tests | 2002 |
[Acquisition of secondary resistance after failure of a first treatment of Helicobacter pylori infection in children].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Age Factors; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Child, Preschool; Clarithromycin; Data Interpretation, Statistical; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Infant; Lansoprazole; Male; Metronidazole; Omeprazole; Penicillin Resistance; Penicillins; Retrospective Studies | 2002 |
Evaluation of the Helicobacter pylori stool antigen test for monitoring eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Antigens; Clarithromycin; Feces; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Prospective Studies; Sensitivity and Specificity; Time Factors; Treatment Outcome | 2002 |
[Gastroduodenal ulcer in childhood].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Informed Consent; Japan; Lansoprazole; Male; Omeprazole; Peptic Ulcer; Practice Guidelines as Topic; Treatment Failure | 2002 |
Failure of Helicobacter pylori eradication: is poor compliance the main cause?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Patient Compliance; Penicillins; Peptic Ulcer; Treatment Failure | 2002 |
[Eradication of helicobacter pylori: symptomatic treatment of reflux disease?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Esophagitis, Peptic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Randomized Controlled Trials as Topic | 2002 |
Improvement of long-standing iron-deficiency anemia in adults after eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Female; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Hematologic Tests; Humans; Lansoprazole; Omeprazole; Penicillins; Treatment Outcome | 2002 |
Effect of Helicobacter pylori eradication on platelet recovery in Japanese patients with chronic idiopathic thrombocytopenic purpura and secondary autoimmune thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Blood Platelets; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Immunosuppressive Agents; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Platelet Count; Purpura, Thrombocytopenic, Idiopathic | 2002 |
Localization of [14C]clarithromycin in rat gastric tissue when administered with lansoprazole and amoxicillin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Amoxicillin; Animals; Carbon Radioisotopes; Clarithromycin; Drug Interactions; Gastric Mucosa; Injections, Intravenous; Intestinal Mucosa; Intubation, Gastrointestinal; Lansoprazole; Male; Omeprazole; Rats; Rats, Wistar; Stomach | 2002 |
Normalization of phospholipids concentration of the gastric mucosa was observed in patients with peptic ulcer after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Phospholipids; Stomach Ulcer; Treatment Outcome | 2002 |
One week regimen of esomeprazole based triple therapy is sufficient for duodenal ulcer healing and Helicobacter pylori eradication in patients with duodenal ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Esomeprazole; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Prospective Studies; Treatment Outcome | 2002 |
Effects of clarithromycin and amoxicillin on gastric emptying in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Infective Agents; Carbon Radioisotopes; Clarithromycin; Drug Therapy, Combination; Duodenum; Gastric Emptying; Gastric Mucosa; Lansoprazole; Male; Omeprazole; Rats; Rats, Wistar | 2002 |
Regression of CD5-positive and Helicobacter pylori-negative mucosa-associated lymphoid tissue lymphoma of the rectum after administration of antibiotics: report of a case.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; CD5 Antigens; Clarithromycin; Colonoscopy; Drug Therapy, Combination; Female; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Omeprazole; Penicillins; Rectal Neoplasms | 2002 |
Long-term follow-up of gastric metaplasia after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Cicatrix; Convalescence; Drug Therapy, Combination; Duodenal Ulcer; Duodenoscopy; Female; Follow-Up Studies; Gastric Acid; Gastric Mucosa; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Metaplasia; Metronidazole; Middle Aged; Mucus; Omeprazole; Severity of Illness Index | 2003 |
Utility and limitations of a method for detecting Helicobacter pylori-specific antigens in the stool.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Antigens, Bacterial; Breath Tests; Drug Therapy, Combination; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Feces; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors; Sensitivity and Specificity | 2003 |
Smoking and polymorphisms of fucosyltransferase gene Le affect success of H. pylori eradication with lansoprazole, amoxicillin, and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Female; Fucosyltransferases; Genotype; Helicobacter pylori; Humans; Lansoprazole; Lewis Blood Group Antigens; Male; Middle Aged; Omeprazole; Polymorphism, Genetic; Prospective Studies; Smoking | 2003 |
Isolated granulomatous gastritis successfully treated by Helicobacter pylori eradication: a possible association between granulomatous gastritis and Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Gastric Mucosa; Gastritis; Granuloma; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Middle Aged; Omeprazole | 2003 |
Low dose, one-week triple therapy (lanzoprazole, amoxycillin, clarithromycin) for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Proton Pump Inhibitors; Stomach Ulcer; Treatment Outcome | 2003 |
Levofloxacin based triple therapy as a second-line treatment after failure of helicobacter pylori eradication with standard triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Treatment Failure | 2003 |
Retreatment of H. pylori with dual therapy using high doses of rabeprazole or lansoprazole can be effective.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Retreatment; Treatment Outcome | 2003 |
Does eradication of Helicobacter pylori reduce the risk of carcinogenesis in the residual stomach after gastrectomy for early gastric cancer? Comparison of mucosal lesions in the residual stomach before and after Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Cell Transformation, Neoplastic; Clarithromycin; Female; Gastrectomy; Gastric Mucosa; Gastroenterostomy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Neoplasm Recurrence, Local; Omeprazole; Stomach Neoplasms; Treatment Outcome | 2004 |
[Successful treatment of long-standing iron-deficiency anemia in adults by eradication of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anemia, Iron-Deficiency; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole | 2004 |
Complete remission of cyclic thrombocytopenia after Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Platelet Count; Remission Induction; Thrombocytopenia | 2004 |
Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Colony Count, Microbial; DNA, Bacterial; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Point Mutation; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Stomach Ulcer; Treatment Outcome | 2004 |
Eradication of Helicobacter pylori induces apoptosis and inhibits proliferation of heterotopic proliferative glands in infected Mongolian gerbils.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Bacterial Agents; Apoptosis; Cell Proliferation; Choristoma; Clarithromycin; Gastric Mucosa; Gerbillinae; Helicobacter Infections; Helicobacter pylori; Intestines; Lansoprazole; Omeprazole; Stomach | 2004 |
Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Proton Pump Inhibitors | 2004 |
Effect of sucralfate on antibiotic therapy for Helicobacter pylori infection in mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Area Under Curve; Chemistry, Pharmaceutical; Clarithromycin; Drug Combinations; Female; Gastritis; Half-Life; Helicobacter Infections; Helicobacter pylori; Hydrogen-Ion Concentration; Immunoglobulin G; Lansoprazole; Mice; Mice, Inbred C57BL; Microscopy, Electron, Scanning; Omeprazole; Penicillins; Sucralfate; Viscosity | 2004 |
Results of triple eradication therapy in Japanese children: a retrospective multicenter study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Child; Child, Preschool; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Humans; Infant; Lansoprazole; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Sulfoxides | 2004 |
Second-line treatment for Helicobacter pylori infection in Japan: proton pump inhibitor-based amoxicillin and metronidazole regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Proton Pump Inhibitors; Retreatment; Time Factors | 2004 |
Amoxicillin resistance in Helicobacter pylori: studies from Tokyo, Japan from 1985 to 2003.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarithromycin; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Rabeprazole; Tokyo | 2005 |
Influence of antimicrobial treatment for Helicobacter pylori infection on the intestinal microflora in Japanese macaques.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Infective Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Clarithromycin; Enterobacteriaceae; Enterococcus; Feces; Helicobacter Infections; Helicobacter pylori; Intestines; Lansoprazole; Macaca; Omeprazole; Proton Pump Inhibitors | 2005 |
Clinical, histological and molecular follow-up of 60 patients with gastric marginal zone lymphoma of mucosa-associated lymphoid tissue.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Infective Agents; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Gene Rearrangement; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulin Heavy Chains; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Omeprazole; Polymerase Chain Reaction; Prognosis; Remission Induction; Stomach Neoplasms | 2005 |
Anti-Helicobacter pylori therapy significantly reduces Helicobacter pylori -induced gastric mucosal damage in Mongolian gerbils.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Gerbillinae; Helicobacter Infections; Helicobacter pylori; Lansoprazole; Male; Omeprazole; Specific Pathogen-Free Organisms | 2005 |
Has Helicobacter pylori eradication therapy any effect on severity of rosacea symptoms?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Administration Schedule; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Rosacea | 2005 |
Effectiveness of omeprazole- versus lansoprazole-based triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Israel; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome | 2005 |
Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Aryl Hydrocarbon Hydroxylases; Biopsy; Clarithromycin; Colony Count, Microbial; Cytochrome P-450 CYP2C19; Endoscopy, Gastrointestinal; Female; Gastric Mucosa; Gastritis; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Mutation; Omeprazole; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; RNA, Bacterial; RNA, Ribosomal, 23S; Treatment Outcome | 2005 |
Helicobacter heilmannii infection: clinical, endoscopic and histopathological features in Japanese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Clarithromycin; Endoscopy, Gastrointestinal; Female; Gastritis; Helicobacter heilmannii; Helicobacter Infections; Humans; Japan; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Male; Microscopy, Electron, Transmission; Middle Aged; Omeprazole; Stomach; Treatment Outcome | 2005 |
Ménétrier's disease in a patient with Helicobacter pylori infection is linked to elevated glucagon-like peptide-2 activity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Gastritis, Hypertrophic; Glucagon-Like Peptide 2; Glucagon-Like Peptides; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Minocycline; Omeprazole; Peptides; Remission Induction | 2005 |
Determinants of non-response in Helicobacter pylori eradication trials.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Treatment Failure | 2005 |
Altered expression of Skp2, c-Myc and p27 proteins but not mRNA after H. pylori eradication in chronic gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Clarithromycin; Cyclin-Dependent Kinase Inhibitor p27; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Immunohistochemistry; Interleukin-8; Lansoprazole; Male; Middle Aged; Omeprazole; Proteins; Proto-Oncogene Proteins c-myc; Proton Pump Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; S-Phase Kinase-Associated Proteins | 2006 |
CagA status and Helicobacter pylori eradication among dyspeptic patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Biomarkers; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Enzyme-Linked Immunosorbent Assay; Eosinophilia; Eosinophils; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphocytes; Male; Middle Aged; Omeprazole; Peptic Ulcer | 2005 |
[The cause of failure of eradication treatment of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Patient Compliance; Treatment Outcome | 2005 |
Improvement of gastrointestinal quality of life scores in cases of Helicobacter pylori-positive functional dyspepsia after successful eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dyspepsia; Female; Gastrointestinal Diseases; Gastrointestinal Motility; Gastrointestinal Tract; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pain Measurement; Quality of Life; Stomach Ulcer; Surveys and Questionnaires | 2005 |
Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Mucosa; Lansoprazole; Male; Omeprazole; Proton Pump Inhibitors; Retrospective Studies; Stomach Ulcer; Treatment Outcome | 2005 |
[Pseudomembranous colitis after Helicobacter pylori eradication therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Therapy, Combination; Enterocolitis, Pseudomembranous; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole | 2006 |
Influence of smoking and CYP2C19 genotypes on H. pylori eradication success.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Polymorphism, Genetic; Smoking; Treatment Outcome | 2007 |
Contrast-enhanced ultrasonographic assessment of the response of Ménétrier disease to Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Contrast Media; Diagnosis, Differential; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Gastritis, Hypertrophic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Middle Aged; Polysaccharides; Ultrasonography | 2006 |
The Efficacy of Helicobacter pylori eradication in the treatment of idiopathic thrombocytopenic purpura--the first study in Turkey.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Purpura, Thrombocytopenic, Idiopathic; Turkey | 2006 |
Evaluation of the efficacy of triple therapy regimen for Helicobacter pylori eradication in gastrectomized patients with gastric adenocarcinoma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Case-Control Studies; Clarithromycin; Drug Therapy, Combination; Female; Gastrectomy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Stomach Neoplasms | 2006 |
Helicobacter pylori eradication reduces platelet count in patients without idiopathic thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Stomach Ulcer | 2007 |
Influence of H pylori on plasma ghrelin in patients without atrophic gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; Ghrelin; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Middle Aged; Peptide Hormones; Turkey | 2007 |
A better cure rate with 800 mg than with 400 mg clarithromycin regimens in one-week triple therapy for Helicobacter pylori infection in cigarette-smoking peptic ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective Agents; Chi-Square Distribution; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Logistic Models; Male; Middle Aged; Retrospective Studies; Smoking; Statistics, Nonparametric; Treatment Outcome | 2007 |
Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Mixed Function Oxygenases; Polymorphism, Restriction Fragment Length; Treatment Outcome | 2007 |
Pyroderma gangrenosum: resolution after treatment for Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Pyoderma Gangrenosum | 2006 |
Endoscopic patterns and histopathological features after eradication therapy in Helicobacter pylori-associated nodular gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alkylating Agents; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Drug Therapy, Combination; Female; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Prospective Studies; Tinidazole; Treatment Outcome | 2008 |
Effect of Helicobacter pylori eradication on gastric carcinogenesis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Amoxicillin; Animals; Animals, Outbred Strains; Anti-Bacterial Agents; Clarithromycin; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Gastritis; Gerbillinae; Helicobacter Infections; Helicobacter pylori; Interferon-gamma; Lansoprazole; Male; Specific Pathogen-Free Organisms; Stomach Neoplasms; Time Factors | 2008 |
The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective Agents; Antibodies, Bacterial; Biopsy; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Japan; Lansoprazole; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Retrospective Studies; Stomach; Stomach Neoplasms; Treatment Outcome | 2008 |
Effect of eradication of Helicobacter pylori on the histology and cellular phenotype of gastric intestinal metaplasia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective Agents; Antibodies; Biopsy; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metaplasia; Middle Aged; Phenotype; Prospective Studies; Stomach; Stomach Neoplasms; Tropomyosin; Tumor Suppressor Protein p53 | 2008 |
Evaluation of antibiotic therapy for eradication of "Candidatus Helicobacter heilmannii".
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Helicobacter heilmannii; Helicobacter Infections; Lansoprazole; Lymphoma; Mice; Mice, Inbred C57BL; Stomach; Stomach Neoplasms; Treatment Outcome | 2008 |
Reflux masquerader: acute Helicobacter pylori infection in neonates and infants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Infant; Lansoprazole; Male; Proton Pump Inhibitors; Treatment Outcome | 2008 |
Characteristics of magnified endoscopic images of gastric extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue, including changes after treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Therapy, Combination; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoid Tissue; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Pilot Projects; Retrospective Studies; Stomach Neoplasms | 2008 |
A case of Cronkhite-Canada syndrome: remission after treatment with anti-Helicobacter pylori regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Alopecia; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Colonic Polyps; Colonoscopy; Gastritis; Helicobacter Infections; Humans; Hyperpigmentation; Intestinal Polyposis; Lansoprazole; Male; Syndrome | 2008 |
[Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Data Interpretation, Statistical; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole | 2008 |
Iron deficiency anemia successfully treated by Helicobacter pylori eradication in a patient with idiopathic thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anemia, Iron-Deficiency; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Treatment Outcome | 2009 |
Ten-day sequential therapy of Helicobacter pylori infection in Thailand.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Patient Compliance; Probability; Prospective Studies; Risk Assessment; Severity of Illness Index; Thailand; Time Factors; Treatment Outcome; Young Adult | 2010 |
How to manage Helicobacter pylori after sequential therapy failure?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Child; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Ofloxacin; Rabeprazole; Treatment Failure; Treatment Outcome | 2010 |
Regression of immunoproliferative small intestinal disease after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Doxycycline; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Immunoproliferative Small Intestinal Disease; Lansoprazole; Male; Omeprazole; Organometallic Compounds; Tinidazole; Young Adult | 2010 |
The effectiveness of packed therapy with three drugs in Helicobacter pylori eradication in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Retrospective Studies | 2010 |
Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Cytochrome P-450 Enzyme System; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Polymorphism, Genetic; Proton Pump Inhibitors | 2010 |
Age-dependent eradication of Helicobacter pylori in Japanese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Aged, 80 and over; Aging; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Logistic Models; Male; Middle Aged; Retrospective Studies; Treatment Failure | 2010 |
Long term changes in platelet counts after H. pylori eradication in non-ITP patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Platelet Count; Purpura, Thrombocytopenic, Idiopathic | 2010 |
Changes in gastric mucosal patterns seen by magnifying NBI during H. pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Gastric Mucosa; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Image Enhancement; Lansoprazole; Male; Middle Aged; Sensitivity and Specificity; Severity of Illness Index | 2011 |
Partial regression of duodenal lesions of intestinal follicular lymphoma after antibiotic treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Clarithromycin; Drug Therapy, Combination; Duodenal Neoplasms; Endoscopy, Gastrointestinal; Humans; Lansoprazole; Lymphoma, Follicular; Male; Middle Aged | 2010 |
Sequential therapy in clarithromycin-sensitive and -resistant Helicobacter pylori based on polymerase chain reaction molecular test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Biopsy; Breath Tests; Chi-Square Distribution; Clarithromycin; DNA, Bacterial; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gastroscopy; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Nitroimidazoles; Odds Ratio; Point Mutation; Polymerase Chain Reaction; Predictive Value of Tests; Proton Pump Inhibitors; Ribotyping; Risk Assessment; Risk Factors; RNA, Ribosomal, 23S; Thailand; Time Factors; Treatment Outcome | 2011 |
Application of levofloxacine in the second phase of sequential therapy regimen for Helicobacter pylori eradication: is it a good choice?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Ofloxacin; Prospective Studies; Treatment Outcome | 2011 |
Development of corpus atrophic gastritis may be associated with Helicobacter pylori-related idiopathic thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Gastritis, Atrophic; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Pepsinogens; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Treatment Outcome | 2011 |
Improvements in Helicobacter pylori eradication rates through clinical CYP2C19 genotyping.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Metronidazole; Middle Aged; Pharmacogenetics; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2011 |
Does long-term aspirin use have any effect on Helicobacter pylori eradication?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Case-Control Studies; Clarithromycin; Drug Resistance, Microbial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Pilot Projects; Prospective Studies; Time Factors; Treatment Outcome | 2011 |
Helicobacter pylori infection-related pancytopenia in a young boy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anemia, Megaloblastic; Anti-Bacterial Agents; Clarithromycin; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Pancytopenia; Vitamin B 12; Vitamin B 12 Deficiency | 2011 |
Mass eradication of Helicobacter pylori: feasible and advisable?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Drugs, Generic; Feasibility Studies; Female; Health Policy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Latin America; Male; Metronidazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2011 |
Role of gastritis pattern on Helicobacter pylori eradication.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2012 |
Comparison of sequential and standard therapy for Helicobacter pylori eradication in children and investigation of clarithromycin resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Child, Preschool; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole | 2012 |
Multiple-antibiotic-resistant Helicobacter pylori infection eradicated with a tailor-made quadruple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Bismuth; Breath Tests; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Gastritis; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Microbial Sensitivity Tests; Minocycline; Phenotype; Proton Pump Inhibitors; Time Factors | 2012 |
[Effect of pharmaceutical care in the diagnosis of Helicobacter pylori infection using 13C-urea breath test].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; False Negative Reactions; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Pharmaceutical Services; Pharmacists; Proton Pump Inhibitors; Surveys and Questionnaires; Urea | 2012 |
Education and imaging. Gastrointestinal: colonic mucosa-associated lymphoid tissue lymphoma regressed by levofloxacin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Colonic Neoplasms; Colonoscopy; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Endosonography; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intestinal Mucosa; Lansoprazole; Levofloxacin; Lymphoma, B-Cell, Marginal Zone; Multimodal Imaging; Occult Blood; Ofloxacin; Polymerase Chain Reaction; Positron-Emission Tomography; Tomography, X-Ray Computed | 2013 |
Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Gastric Acidity Determination; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Metronidazole; Middle Aged; Peptic Ulcer; Pilot Projects; Prospective Studies; Proton Pump Inhibitors; Surveys and Questionnaires; Treatment Outcome | 2013 |
Trends of second-line eradication therapy for Helicobacter pylori in Japan: a multicenter study in the Tokyo metropolitan area.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Disease Eradication; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Retrospective Studies; Tokyo; Young Adult | 2013 |
What is the impact of Helicobacter pylori density on the success of eradication therapy: a clinico-histopathological study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Breath Tests; Case-Control Studies; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Proton Pump Inhibitors; Stomach; Tetracycline; Treatment Outcome; Urea; Young Adult | 2013 |
Complete regression of early-stage gastric diffuse large B-cell lymphoma in an HIV-1-infected patient following Helicobacter pylori eradication therapy.
Topics: Adenine; Amoxicillin; Anti-Bacterial Agents; Antiretroviral Therapy, Highly Active; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; HIV-1; Humans; Lansoprazole; Lymphoma, AIDS-Related; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Tenofovir | 2014 |
Cure rate of Helicobacter pylori infection in Egyptian children related to CYP2C19 gene polymorphism.
Topics: Amoxicillin; Child; Clarithromycin; Cytochrome P-450 CYP2C19; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Proton Pump Inhibitors; Severity of Illness Index; Treatment Outcome | 2014 |
[Ten day concomitant therapy is superior to ten day sequential therapy for Helicobacter pylori eradication].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Logistic Models; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Retrospective Studies; Risk Factors; Treatment Outcome | 2014 |
Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group).
Topics: Amoxicillin; Chronic Disease; Clarithromycin; Disease Eradication; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Time Factors; Tokyo | 2014 |
The effect of Helicobacter pylori eradication on the levels of essential trace elements.
Topics: Adult; Aged; Amoxicillin; Copper; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Selenium; Trace Elements; Zinc | 2014 |
Pediatric Pharyngeal IgD-positive Monoclonal Plasmacytoid and Plasma Cell Neoplasm.
Topics: Adolescent; Amoxicillin; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Clarithromycin; Cyclophosphamide; Diagnosis, Differential; Doxorubicin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Immunocompetence; Immunoglobulin D; Lansoprazole; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Paraproteins; Pharyngeal Neoplasms; Plasma Cells; Plasmablastic Lymphoma; Postoperative Complications; Prednisone; Remission Induction; Tonsillectomy; Vincristine | 2015 |
Efficacy of levofloxacin, amoxicillin and a proton pump inhibitor in the eradication of Helicobacter pylori in Brazilian patients with peptic ulcers.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Brazil; Breath Tests; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Young Adult | 2015 |
Influence of vitamin C and E supplementation on the eradication rates of triple and quadruple eradication regimens for Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Ascorbic Acid; Breath Tests; Clarithromycin; Dietary Supplements; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Organometallic Compounds; Retrospective Studies; Treatment Outcome; Vitamin E; Vitamins; Young Adult | 2015 |
Does the urea breath test predict eradication of Helicobacter pylori infection?
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Carbon Radioisotopes; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome; Urea | 2016 |
High dose amoxicillin-based first line regimen is equivalent to sequential therapy in the eradication of H. pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Retrospective Studies | 2016 |
Severe Helicobacter pylori gastritis-related thrombocytopenia and iron deficiency anemia in an adolescent female.
Topics: Adolescent; Amoxicillin; Anemia, Iron-Deficiency; Breath Tests; Clarithromycin; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulins, Intravenous; Iron; Lansoprazole; Purpura, Thrombocytopenic; Remission Induction | 2016 |
Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Atrophy; Breath Tests; Clarithromycin; Cohort Studies; Female; Follow-Up Studies; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Lansoprazole; Male; Metaplasia; Metronidazole; Middle Aged; Proportional Hazards Models; Proton Pump Inhibitors; Pyloric Antrum; Retrospective Studies; Risk Factors; Stomach; Stomach Neoplasms | 2016 |
The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Monitoring; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Retrospective Studies; Sulfonamides; Treatment Outcome | 2016 |
An assessment of the efficacy of first-line Helicobacter pylori-eradication therapy based on clarithromycin susceptibility.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Retrospective Studies | 2016 |
Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Body Mass Index; Body Weight; Case-Control Studies; Clarithromycin; Drug Therapy, Combination; Endoscopy, Digestive System; Female; Gastric Mucosa; Gastritis, Atrophic; Ghrelin; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Leptin; Male; Middle Aged; Peptic Ulcer | 2016 |
Liquid Chromatographic-Chemometric Techniques for the Simultaneous HPLC Determination of Lansoprazole, Amoxicillin and Clarithromycin in Commercial Preparation.
Topics: Amoxicillin; Chromatography, High Pressure Liquid; Clarithromycin; Lansoprazole; Linear Models; Multivariate Analysis; Reproducibility of Results; Tablets | 2017 |
Helicobacter pylori eradication may successfully treat primary cutaneous follicle center lymphoma.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Doxycycline; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell; Metronidazole; Middle Aged; Organometallic Compounds; Rabeprazole; Salicylates | 2018 |
Population Scale Retrospective Analysis Reveals Potential Risk of Cholestasis in Pregnant Women Taking Omeprazole, Lansoprazole, and Amoxicillin.
Topics: Adolescent; Adult; Amoxicillin; Child; Cholestasis; Drug Therapy, Combination; Female; Humans; Lansoprazole; Male; Middle Aged; Odds Ratio; Omeprazole; Pregnancy; Retrospective Studies; Risk Factors; Young Adult | 2019 |
Helicobacter suis infection is associated with nodular gastritis-like appearance of gastric mucosa-associated lymphoid tissue lymphoma.
Topics: Adult; Amoxicillin; Clarithromycin; DNA, Bacterial; Drug Therapy, Combination; Gastritis; Helicobacter heilmannii; Helicobacter Infections; Humans; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Prevalence; Treatment Outcome | 2019 |
Characteristics of cutaneous adverse drug reactions caused by triple-combination drug therapy used for Helicobacter pylori eradication.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Erythema Multiforme; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Sex Factors; Stevens-Johnson Syndrome; Sulfonamides | 2020 |
Gastric mucosal changes, and sex differences therein, after Helicobacter pylori eradication: A long-term prospective follow-up study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Atrophy; Clarithromycin; Female; Follow-Up Studies; Gastric Mucosa; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metaplasia; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Sex Factors; Young Adult | 2021 |
RP-HPLC-DAD Method Development and Validation for Simultaneous Determination of Lansoprazole, Tinidazole, Amoxicillin, and Naproxen in Their Raw Materials and Combined Dosage Form: DOE Approach for Optimization of the Proposed Method.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Naproxen; Omeprazole; Research Design; Tinidazole | 2022 |